157 results on '"Alfred J. Saah"'
Search Results
2. Anogenital Human Papillomavirus (HPV) Infection, Seroprevalence, and Risk Factors for HPV Seropositivity Among Sexually Active Men Enrolled in a Global HPV Vaccine Trial
- Author
-
Christine Velicer, Anna R. Giuliano, Alfred J. Saah, Joel M. Palefsky, Stephen E. Goldstone, Brady Dubin, Joseph E. Tota, and Alain Luxembourg
- Subjects
Male ,Microbiology (medical) ,Sexually Transmitted Diseases ,HPV vaccines ,Alphapapillomavirus ,Men who have sex with men ,law.invention ,Sexual and Gender Minorities ,Condom ,Risk Factors ,Seroepidemiologic Studies ,law ,Prevalence ,Humans ,Medicine ,Seroprevalence ,Papillomavirus Vaccines ,Homosexuality, Male ,Papillomaviridae ,business.industry ,Papillomavirus Infections ,Vaccine trial ,HPV infection ,virus diseases ,Odds ratio ,medicine.disease ,Vaccination ,Infectious Diseases ,business ,Demography - Abstract
Background In men, the incidence of human papillomavirus (HPV)–related cancer is rising, but data regarding male HPV infection and seroprevalence are available from only a few countries. Methods This analysis of a global HPV vaccine trial evaluated baseline data from 1399 human immunodeficiency virus–negative heterosexual men (HM) and men who have sex with men (MSM). Key objectives included assessment of HPV prevalence and risk factors for seropositivity to 9-valent HPV (9vHPV) vaccine types (6, 11, 16, 18, 31, 33, 45, 52, and 58), and concordance between seropositivity and prevalent HPV type. Results Overall, 455 of 3463 HM (13.1%) and 228 of 602 MSM (37.9%) were HPV DNA positive for any 9vHPV vaccine type at baseline. Infection prevalence and seroprevalence (≥1 9vHPV vaccine type) were 13.2% and 8.1%, respectively, among 333 HM from Europe, and 37.9% and 29.9%, respectively, among 335 MSM from Europe or North America. Among men with baseline infection, MSM had higher seroprevalence for concordant HPV types (39.5% vs 10.8% in HM). The seropositivity risk (irrespective of baseline infection status) was higher among MSM versus HM (age-adjusted odds ratio, 3.0 [95% confidence interval, 2.4–6.4]). Among MSM, statistically significant seropositivity risk factors included younger age at sexual debut, higher number of receptive anal sex partners, and less frequent condom use. No factors assessed were associated with seropositivity in HM. Conclusions Higher proportions of MSM than HM were HPV DNA positive and seropositive, and concordance between HPV DNA positivity and seropositivity, a potential marker of true infection versus carriage, was higher in MSM. Most MSM and HM were seronegative for all 9vHPV vaccine types, suggesting the potential benefit of catch-up vaccination after sexual debut. Clinical Trials Registration. NCT00090285.
- Published
- 2021
3. Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence
- Author
-
G. Yen, Hanane Khoury, D. Badgley, Smita Kothari, Elmar A. Joura, Margaret Stanley, Gonzalo Perez, Darron R. Brown, Alain Luxembourg, Anuj Walia, and Alfred J. Saah
- Subjects
medicine.medical_specialty ,Cross Protection ,Uterine Cervical Neoplasms ,HPV vaccines ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,030225 pediatrics ,Statistical significance ,Internal medicine ,Humans ,Medicine ,Papillomavirus Vaccines ,030212 general & internal medicine ,Randomized Controlled Trials as Topic ,General Veterinary ,General Immunology and Microbiology ,business.industry ,Incidence (epidemiology) ,Papillomavirus Infections ,Public Health, Environmental and Occupational Health ,Vaccine efficacy ,Confidence interval ,Infectious Diseases ,Systematic review ,Molecular Medicine ,Female ,Observational study ,business - Abstract
Background The extent of cross-protection provided by currently licensed bivalent and quadrivalent HPV vaccines versus direct protection against HPV 31-, 33-, 45-, 52-, and 58-related disease is debated. A systematic literature review was conducted to establish the duration and magnitude of cross-protection in interventional and observational studies. Methods PubMed and Embase databases were searched to identify randomized controlled trials (RCT) and observational studies published between 2008 and 2019 reporting on efficacy and effectiveness of HPV vaccines in women against non-vaccine types 31, 33, 45, 52, 58, and 6 and 11 (non-bivalent types). Key outcomes of interest were vaccine efficacy against 6- and 12-month persistent infection or genital lesions, and type-specific genital HPV prevalence or incidence. RCT data were analyzed for the according-to-protocol (bivalent vaccine) or negative-for-14-HPV-types (quadrivalent vaccine) efficacy cohorts. Results Data from 23 RCTs and 33 observational studies evaluating cross-protection were extracted. RCTs assessed cross-protection in post-hoc analyses of small size subgroups. Among fully vaccinated, baseline HPV-naive women, the bivalent vaccine showed statistically significant cross-protective efficacy, although with wide confidence intervals, against 6-month and 12-month persistent cervical infections and CIN2+ only consistently for HPV 31 and 45, with the highest effect observed for HPV 31 (range 64.6% [95% CI: 27.6 to 83.9] to 79.1% [97.7% CI: 27.6 to 95.9] for 6-month persistent infection; maximal follow-up 4.7 years). No cross-protection was shown in extended follow-up. The quadrivalent vaccine efficacy reached statistical significance for HPV 31 (46.2% [15.3–66.4]; follow-up: 3.6 years). Similarly, observational studies found consistently significant effectiveness only against HPV 31 and 45 with both vaccines. Conclusions RCTs and observational studies show that cross-protection is inconsistent across non-vaccine HPV types and is largely driven by HPV 31 and 45. Furthermore, existing data suggest that it wanes over time; its long-term durability has not been established.
- Published
- 2021
4. Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines
- Author
-
Alain Luxembourg, Gonzalo Perez, G. Yen, Hanane Khoury, Elmar A. Joura, Alfred J. Saah, Darron R. Brown, Margaret Stanley, Anuj Walia, D. Badgley, and Smita Kothari
- Subjects
Cross Protection ,030231 tropical medicine ,Bivalent (genetics) ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,Humans ,Medicine ,Papillomavirus Vaccines ,Vaccines, Combined ,030212 general & internal medicine ,Seroconversion ,Neutralizing antibody ,General Veterinary ,General Immunology and Microbiology ,biology ,business.industry ,Papillomavirus Infections ,Public Health, Environmental and Occupational Health ,Antibodies, Neutralizing ,Vaccination ,Titer ,Infectious Diseases ,Systematic review ,Immunology ,biology.protein ,Molecular Medicine ,Antibody ,business - Abstract
Introduction Studies on the cross-protective effect of HPV bivalent and quadrivalent vaccines demonstrated inconsistent findings against additional HPV types covered by the nonavalent vaccine. The objective of this study was to conduct a systematic literature review to assess the consistency and durability of the cross-protective neutralizing antibody immune responses of the currently licensed bivalent and quadrivalent vaccines to non-vaccine HPV types targeted by the nonavalent vaccine (HPV 6, 11, 31, 33, 45, 52, and 58). Methods PubMed and EMBASE databases were searched from 2008 to 2019 to identify studies reporting antibody/immune response after vaccination with either the bivalent, quadrivalent, or nonavalent vaccine. Key outcomes were seroconversion, seropositivity or geometric mean titers against HPV types 6, 11, 31, 33, 45, 52, and 58. Results Eighteen publications met inclusion criteria, reporting on 14 interventional and five observational studies. Across all studies, immune responses to non-vaccine high-risk HPV types after bivalent vaccination were higher than baseline or quadrivalent vaccine. Nonavalent vaccine elicited near total seroconversion to HPV types 31, 33, 45, 52, and 58, with seropositivity remaining near 100% up to 24 months post-dose 1. In contrast, bivalent and quadrivalent vaccination resulted in lower seroconversion levels for non-vaccine types, which waned over time. Conclusions The cross-protection antibody/immune response among participants having received all three doses of bivalent or quadrivalent vaccine is not comparable to the specific response elicited by HPV vaccine types. Even in cases where a statistically significant cross-reactive immunological response is reported, long-term data on the duration of the response beyond two years are very limited. Further, the lack of a standard for assays limits comparability of results between studies.
- Published
- 2021
5. Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review
- Author
-
Wei (Vivian) Wang, Smita Kothari, Jozica Skufca, Anna R. Giuliano, Karin Sundström, Mari Nygård, Carol Koro, Marc Baay, Thomas Verstraeten, Alain Luxembourg, Alfred J. Saah, and Suzanne M. Garland
- Subjects
Male ,Pharmacology ,Papillomavirus Infections ,Vaccination ,Drug Discovery ,Immunology ,Humans ,Uterine Cervical Neoplasms ,Molecular Medicine ,Female ,Papillomavirus Vaccines ,Papillomaviridae - Abstract
Human papillomavirus (HPV) infection, which poses significant disease burden, is decreasing following implementation of vaccination programs. Synthesized evidence on HPV vaccine real-world benefit was published in 2016. However, long-term impact of vaccination, and how vaccination programs influence infection rates and disease outcomes, requires further examination. We systematically reviewed observational studies on HPV vaccination within MEDLINE, EMBASE, and Google Scholar from 2016 to 2020, involving 14 years of follow-up data. We identified 138 peer-reviewed publications reporting HPV vaccine impact or effectiveness. Outcomes of interest included rates of infection at different anatomical sites and incidence of several HPV-related disease endpoints. The expansion of HPV vaccination programs worldwide has led to a reduction in genital infection and significant decreases in incidence of HPV-related disease outcomes. Therefore, the WHO has set goals for the elimination of cervical cancer as a public health concern. To track progress toward this requires an understanding of the effectiveness of different vaccination initiatives. However, the impact on males, and potential benefit of gender-neutral vaccination programs have not been fully explored. To present an accurate commentary on the current outlook of vaccination and to help shape policy therefore requires a systematic review of available data.
- Published
- 2022
- Full Text
- View/download PDF
6. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up
- Author
-
Yuanzheng Qiu, You-Lin Qiao, Chao Zhao, Xing Xie, Yun Zhao, Wen Chen, Alfred J. Saah, Qiong Shou, Xueyan Liao, Shaoming Wang, Lihui Wei, and Jihong Liu
- Subjects
Adult ,China ,medicine.medical_specialty ,030231 tropical medicine ,Population ,Placebo-controlled study ,Uterine Cervical Neoplasms ,Phases of clinical research ,Placebo ,law.invention ,Placebos ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Asian People ,Double-Blind Method ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,education ,Immunization Schedule ,Colposcopy ,Cervical cancer ,education.field_of_study ,General Veterinary ,General Immunology and Microbiology ,medicine.diagnostic_test ,business.industry ,Papillomavirus Infections ,Public Health, Environmental and Occupational Health ,Genitalia, Female ,Middle Aged ,medicine.disease ,Vaccine efficacy ,Treatment Outcome ,Infectious Diseases ,Molecular Medicine ,Female ,business ,Follow-Up Studies - Abstract
Background A quadrivalent human papillomavirus vaccine (qHPV; HPV6/11/16/18) has demonstrated efficacy and effectiveness worldwide. We report qHPV vaccine efficacy for up to 6.5 years after first administration among Chinese women 20–45 years of age. Methods In this randomized, double-blind, placebo-controlled, multicenter, Phase 3 study (NCT00834106), women were randomized 1:1 to receive 3 doses of qHPV vaccine or placebo (Day 1, Month 2, Month 6). Endo-ecto-cervical and external genital swabs were collected for HPV testing and gynecologic examinations, and cervical cytology testing were performed at Day 1 and Months 7, 12, 18, 24, 30, 42, 54, 66, and 78. Any abnormality in cytology testing would trigger colposcopy examination and cervical biopsy, if necessary. Efficacy against genital disease, persistent infection, and the composite endpoint was assessed. Primary efficacy analyses were conducted in the per-protocol efficacy (PPE) population. Results Of 3006 participants randomized, 2759 (91.8%) and 2374 (79%) completed the Month 30 and Month 78 visits, respectively. At Month 78, efficacy among women aged 20–45 years was 100% (95% CI: 32.3, 100; 0 vs 7 cases) and 100% (95% CI: 70.9, 100; 0 vs 14 cases) against HPV16/18-related cervical intraepithelial neoplasia Grade 2 or 3, adenocarcinoma in situ, and cervical cancer (CIN 2+) and HPV6/11/16/18-related CIN 1+, respectively, in the PPE population. The efficacy against cervical 6-month and 12-month persistent infection was 91.6% (95% CI: 66.0, 99.0) and 97.5% (95% CI: 85.1, 99.9) at Month 30 and Month 78, respectively, in the PPE population. The vaccine also reduced the rate of cervical cytology abnormalities associated with HPV6/11/16/18, with an efficacy of 94.0% (95% CI: 81.5, 98.8). The vaccine was generally well tolerated (reported separately). Conclusion The qHPV vaccine is efficacious against endpoints of persistent infection and genital precancerous lesions in Chinese women aged 20–45 years.
- Published
- 2019
7. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up
- Author
-
Jihong Liu, Yun Zhao, Wen Chen, Jingran Li, Lihui Wei, Qiong Shou, Alfred J. Saah, Chao Zhao, Minghuan Zheng, You-Lin Qiao, Shaoming Wang, Xing Xie, and Xueyan Liao
- Subjects
Adult ,China ,medicine.medical_specialty ,030231 tropical medicine ,Human papillomavirus vaccine ,Antibodies, Viral ,Placebo ,law.invention ,Double blind ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Asian People ,Double-Blind Method ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Adverse effect ,Vaccine Potency ,Safety surveillance ,General Veterinary ,General Immunology and Microbiology ,business.industry ,Papillomavirus Infections ,Vaccination ,Public Health, Environmental and Occupational Health ,Middle Aged ,Clinical trial ,Infectious Diseases ,Molecular Medicine ,Female ,business ,Follow-Up Studies - Abstract
Background A quadrivalent human papillomavirus (qHPV) vaccine (HPV6/11/16/18) has demonstrated efficacy and acceptable safety in international studies. However, these studies did not include participants from mainland China, which has a substantial burden of HPV-related disease. This is the first safety report with a follow-up period of up to 90 months from a randomized, double-blind, placebo-controlled trial of qHPV vaccine in Chinese women 20–45 years of age. Methods Participants were randomized 1:1 to receive three doses of qHPV vaccine or placebo (Day 1, Month 2, and Month 6). Efficacy outcomes are reported elsewhere. Injection-site and systemic adverse events (AEs) were collected using vaccination report cards (VRCs) for 15 days following each vaccination. Serious AEs (SAEs), pregnancy outcomes, new medical conditions, and fetal/infant SAEs were collected during the entire study. Results Of 3006 participants randomized, AEs were reported by 926 (61.8%) qHPV vaccine recipients and 856 (57.1%) placebo recipients over the entire study. Four participants (two in each group) discontinued the study vaccination due to AEs that were considered vaccination-related. Within 15 days following any vaccination, injection-site AEs prompted for on the VRC were more frequent among qHPV vaccine recipients (37.6% vs 27.8%), and systemic AEs prompted for on the VRC were similar in frequency between qHPV vaccine and placebo groups (46.8% vs 45.1%). Thirty-eight and 43 participants reported SAEs in qHPV vaccine and placebo groups, respectively. No SAE was considered qHPV vaccine-related. Pregnancy outcomes, fetal/infant SAEs, and new medical conditions were generally similar in frequency between the qHPV vaccine and placebo groups, and within normal ranges. Conclusion The qHPV vaccine was well tolerated and demonstrated a favorable safety profile in Chinese women 20–45 years of age, consistent with findings from global trials and safety surveillance studies. Trial registration : clinicaltrials.gov ; NCT00834106.
- Published
- 2019
8. Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1
- Author
-
Cynthia Firnhaber, Jennifer Webster-Cyriaque, Judith A. Aberg, Michelle S. Cespedes, Beatriz Grinsztejn, Alfred J. Saah, Susan Cu-Uvin, Triin Umbleja, Erna M. Kojic, Minhee Kang, Reena Masih, and Catherine Godfrey
- Subjects
0301 basic medicine ,NIDCR, National Institute of Dental and Craniofacial Research ,Physiology ,Anal Canal ,HIV Infections ,mMU, milliMerck units ,Cervix Uteri ,Anogenital ,Antibodies, Viral ,ART, antiretroviral therapy ,0302 clinical medicine ,DNA, deoxyribonucleic acid ,NIH, National Institutes of Health ,PCR, polymerase chain reaction ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,Prevalence ,030212 general & internal medicine ,Prospective Studies ,CIN, cervical intraepithelial neoplasia ,NA-ACCORD, North American AIDS Cohort Collaboration on Research and Design ,biology ,Antibody titer ,virus diseases ,Anal canal ,Immunogenicity ,3. Good health ,Vaccination ,HIV, human immunodeficiency virus ,Titer ,Infectious Diseases ,medicine.anatomical_structure ,NIAID, National Institute of Allergy and Infectious Diseases ,WIHS, Women's Interagency HIV Study (WIHS) ,GMT, geometric mean titers ,Female ,nHPV, nonavalent human papillomavirus vaccine ,Antibody ,Adult ,HPV ,Adolescent ,Quadrivalent HPV vaccine ,HPV, human papillomavirus ,Article ,qHPV, quadrivalent human papillomavirus vaccine ,lcsh:Infectious and parasitic diseases ,03 medical and health sciences ,Young Adult ,Acquired immunodeficiency syndrome (AIDS) ,Virology ,medicine ,Humans ,Women ,lcsh:RC109-216 ,Seroconversion ,Cervix ,VIN, vaginal intraepithelial neoplasia ,business.industry ,Papillomavirus Infections ,HIV ,medicine.disease ,030112 virology ,FDA, Food and Drug Administration ,Antibodies, Neutralizing ,AMC, AIDS Malignancy Consortium ,CI, confidence interval ,DNA, Viral ,biology.protein ,business ,ACTG, AIDS Clinical Trials Group ,Immunologic Memory - Abstract
Objectives: People living with HIV have increased Human Papillomavirus (HPV) related lesions and malignancies. We describe HPV DNA recovered from the cervix and anal canal, explore the effect of vaccination on HPV detection, and examine the durability of vaccine titers in women living with HIV-1 who were vaccinated with the quadrivalent HPV vaccine. Methods: AIDS Clinical Trials Group A5240 was a prospective study of the quadrivalent HPV (qHPV) vaccine in 315 HIV-1 infected women in three CD4 strata (A: >350, B; 201–350, C: ≤200 cells/mm3). Vaccine was administered at entry, week 8 and week 24. Cervical and anal HPV DNA specimens were collected at baseline, weeks 28 and 52; serum for antibody testing was obtained at baseline, weeks 28 and 72. Results: Vaccine antibody titers decreased across all four HPV types at week 72 compared to week 28. Lower proportions of sustained seropositivity were observed in women with lower CD4 counts for all four vaccine types, with the lowest titers for HPV 18. Despite the decrease, the geometric mean titer levels were above the seroconversion cut-off levels for all types except HPV 18 in the lowest CD4 stratum. Of the 174 participants who had a negative baseline HPV 16 antibody and developed antibody response at week 28, 95%, 88%, and 86% retained seropositivity at week 72 in strata A, B, and C respectively. Lower antibody retention was observed in women with CD4 350 (p = 0.016). Anal HPV detection was more prevalent compared to cervical detection at all visits. Among high risk types, type 52, 31, 16, 18 and 51 were the most common in the cervical compartment, while types 16, 35, 18, and 51 were the most prevalent in the anal canal at baseline (listed in the order of prevalence). Later detection of HPV not present at baseline was uncommon in either compartment. Serial recovery of HPV over time was more commonly observed in the anal canal. Conclusion: The qHPV vaccine elicits durable titer response above the seroconversion cut-off levels in HIV-infected women. However, the titer levels were substantially lower by Week 72, most noticeably in type 18. HPV DNA was detected more frequently in the anal canal. Detection of non-vaccine high risk HPV suggests a role for the nonavalent vaccine. Keywords: HPV, HIV, Anogenital, Quadrivalent HPV vaccine, Women, Immunogenicity
- Published
- 2018
9. Three-Year Follow-up of 2-Dose Versus 3-Dose HPV Vaccine
- Author
-
Eli Engel, Richard Tytus, Katrina M. Nolan, Simon Dobson, Shelly Senders, Daron G. Ferris, Zafer Kurugöl, Oliver Bautista, Sandhya Sankaranarayanan, Javier Díez-Domingo, Alain Luxembourg, Li-Min Huang, Punnee Pitisuttithum, Surita Roux, Alfred J. Saah, Richard E. Rupp, Andrea Schilling, Lone Kjeld Petersen, Young Tae Kim, Jacob Bornstein, Yae Jean Kim, Hany Ariffin, and Ege Üniversitesi
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Dose-Response Relationship, Immunologic ,Human Papilloma Virus Vaccine ,Alphapapillomavirus ,Antibodies, Viral ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,030225 pediatrics ,Internal medicine ,medicine ,Humans ,Papillomavirus Vaccines ,Human papillomavirus ,Child ,medicine.diagnostic_test ,biology ,business.industry ,Immunogenicity ,Vaccination ,Titer ,Regimen ,[No Keyword] ,Immunoassay ,Pediatrics, Perinatology and Child Health ,biology.protein ,Female ,Antibody ,business ,Biomarkers ,Follow-Up Studies - Abstract
BACKGROUND AND OBJECTIVES: Human papillomavirus (HPV) antibody responses to the 9-valent human papillomavirus (9vHPV) vaccine among girls and boys (aged 9-14 years) receiving 2-dose regimens (months 0, 6 or 0, 12) were noninferior to a 3-dose regimen (months 0, 2, 6) in young women (aged 16-26 years) 4 weeks after last vaccination in an international, randomized, open-label trial (NCT01984697). We assessed response durability through month 36. METHODS: Girls received 2 (months 0 and 6 [0, 6]: n = 301; months 0 and 12 [0, 12]: n = 151) or 3 doses (months 0,2, and 6 [0, 2, 6]: n = 301); boys received 2 doses ([0, 6]: n = 301; [0, 12]: n = 150); and young women received 3 doses ([0, 2, 6]: n = 314) of 9vHPV vaccine. Anti-HPV geometric mean titers (GMTs) were assessed by competitive Luminex immunoassay (cLIA) and immunoglobulin G-Luminex immunoassay (IgG-LIA) through month 36. RESULTS: Anti-HPV GMTs were highest 1 month after the last 9vHPV vaccine regimen dose, decreased sharply during the subsequent 12 months, and then decreased more slowly. GMTs 2 to 2.5 years after the last regimen dose in girls and boys given 2 doses were generally similar to or greater than GMTs in young women given 3 doses. Across HPV types, most boys and girls who received 2 doses (cLIA: 81%-100%; IgG-LIA: 91%-100%) and young women who received 3 doses (cLIA: 78%-98%; IgG-LIA: 91%-100%) remained seropositive 2 to 2.5 years after the last regimen dose. CONCLUSIONS: Antibody responses persisted through 2 to 2.5 years after the last dose of a 2-dose 9vHPV vaccine regimen in girls and boys. in girls and boys, antibody responses generated by 2 doses administered 6 to 12 months apart may be sufficient to induce high-level protective efficacy through at least 2 years after the second dose., Merck Sharp Dohme CorpMerck & Company, Funded by Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc, Kenilworth, NJ.
- Published
- 2021
10. A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298
- Author
-
Qinghua Feng, Rachel M. Presti, Barbara Bastow, Elizabeth Y. Chiao, Joan Dragavon, Timothy J. Wilkin, Robert W. Coombs, Ross D. Cranston, Catherine Godfrey, Alfred J. Saah, Jorge Leon-Cruz, Huichao Chen, Jennifer Webster-Cyriaque, and Michelle S. Cespedes
- Subjects
Adult ,Male ,Microbiology (medical) ,medicine.medical_specialty ,Population ,Human Papilloma Virus Vaccine ,Anal Canal ,HIV Infections ,HPV vaccines ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,Acquired immunodeficiency syndrome (AIDS) ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,education ,Papillomaviridae ,Vaccine Potency ,Articles and Commentaries ,Mouth ,education.field_of_study ,business.industry ,Papillomavirus Infections ,Anal dysplasia ,Middle Aged ,Anal Infection ,Anus Neoplasms ,medicine.disease ,Vaccine efficacy ,Clinical trial ,Oropharyngeal Neoplasms ,Infectious Diseases ,030220 oncology & carcinogenesis ,Early Termination of Clinical Trials ,Female ,business ,Medical Futility ,Brazil - Abstract
Background Adults living with human immunodeficiency virus (HIV) are at increased risk for anal and oropharyngeal cancer caused by human papillomavirus (HPV). The efficacy of HPV vaccines in this population is unknown. Methods In this phase 3, double-blind, randomized, controlled trial, we assigned HIV-infected adults aged ≥27 years to the quadrivalent HPV (types 6, 11, 16, 18) vaccine or placebo (1:1) stratified by sex and presence of anal high-grade squamous intraepithelial lesions on biopsy (bHSIL). The primary endpoint was vaccine efficacy against incident persistent anal infection with quadrivalent vaccine types or single detection at the final visit that were not present at baseline. Secondary endpoints included vaccine efficacy for anal bHSIL after week 52, persistent oral HPV infection. Results A total of 575 participants were randomized. The Data and Safety Monitoring Board stopped the study early due to futility. Vaccine efficacy was 22% (95.1% confidence interval [CI], -31%, 53%) for prevention of persistent anal infection or single detection at the final visit, 0% (95% CI -44%, 31%) for improving bHSIL outcomes and 88% (95.1% CI 2%, 98%) for preventing persistent oral HPV infection, but was 32% (95.1% CI -80%, 74%) for 6-month persistent oral HPV infection or single detection at the final visit. Conclusions These results do not support HPV vaccination of HIV-infected adults aged ≥27 years to prevent new anal HPV infections or to improve anal HSIL outcomes. However, our data suggest a role for prevention of oral HPV infections, but this finding should be confirmed in future studies. Clinical trials registration NCT01461096.
- Published
- 2018
11. Intention-to-prevent analyses for estimating human papillomavirus vaccine efficacy in clinical studies
- Author
-
Alain Luxembourg, Alfred J. Saah, Oliver Bautista, and Gonzalo Perez
- Subjects
HPV ,medicine.medical_specialty ,Population ,HPV vaccines ,Human papillomavirus vaccine ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,030212 general & internal medicine ,education ,Pharmacology ,lcsh:R5-920 ,education.field_of_study ,business.industry ,HPV infection ,virus diseases ,Population effect ,General Medicine ,Vaccine efficacy ,medicine.disease ,female genital diseases and pregnancy complications ,Clinical trial ,Vaccination ,Regimen ,030220 oncology & carcinogenesis ,Immunology ,lcsh:Medicine (General) ,business ,Vaccine - Abstract
HPV vaccine efficacy trials have been conducted in populations exposed to HPV infection (i.e., sexually active individuals); participants were not excluded from participating in the trials based on their HPV status at baseline. Thus, some participants could have been infected at baseline with 1 or more vaccine HPV types. Because HPV vaccines are prophylactic and do not affect existing HPV infections, prophylactic efficacy was assessed in a per-protocol population (those not infected at enrollment to the HPV type being analyzed who also completed the 3-dose regimen of vaccine and had no protocol violations). Supportive intention-to-treat (ITT) and modified ITT, were also conducted to include those with prevalent HPV infection. ITT analyses included those who received ≥1 dose of vaccine and had efficacy follow-up regardless of whether or not they were infected with HPV prior to vaccination. Efficacy in the ITT population simply reflects the amount of prevalent infection in a particular population of study subjects. Intention-to-prevent (ITP) analyses included those who received one dose of vaccine, had efficacy follow-up, and were not infected at enrollment to the HPV type being analyzed.While all of these analyses have been presented, there has been little discussion regarding their respective significance. In this methodological review, we show that an ITT analysis does not preserve an unbiased comparison of treatment groups in relation to estimating prophylactic HPV vaccine efficacy. Furthermore, ITP is more suitable at preserving an unbiased comparison of treatment groups in relation to estimating prophylactic HPV vaccine efficacy. Keywords: HPV, Vaccine, Clinical trial, Population effect
- Published
- 2017
12. Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine
- Author
-
Jennifer S. Read, Adriana Weinberg, William A. Meyer, Myron J. Levin, Alfred J. Saah, Anna-Barbara Moscicki, Sharon Huang, Kelly Richardson, and Lin-Ye Song
- Subjects
Male ,0301 basic medicine ,Time Factors ,030106 microbiology ,Immunization, Secondary ,HIV Infections ,Antibodies, Viral ,Placebo ,Article ,Persistence (computer science) ,Placebos ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,Immunity ,Humans ,Medicine ,030212 general & internal medicine ,Child ,Immunoassay ,General Veterinary ,General Immunology and Microbiology ,biology ,medicine.diagnostic_test ,business.industry ,Papillomavirus Infections ,Public Health, Environmental and Occupational Health ,Antibody titer ,Vaccination ,Infectious Diseases ,Immunology ,biology.protein ,Molecular Medicine ,Female ,Antibody ,business ,Follow-Up Studies - Abstract
Objective Although HIV-infected children are recommended to receive quadrivalent human papillomavirus vaccine (QHPV) there is limited information on their response to QHPV. This study in HIV-infected children, evaluated the magnitude and duration of immune responses to QHPV. This report describes type-specific serum antibody responses over a 4-to-5 year period after either 3 or 4 doses of QHPV. Design/methods HIV-infected children, ages 7-to-11 years, received 3 doses of QHPV (n = 96) or placebo (n = 30). At 72 weeks QHPV recipients received a fourth dose (n = 84), while placebo recipients began the 3-dose QHPV schedule (n = 27). HPV serotype-specific antibody was determined, by competitive Luminex immunoassay (cLIA) and IgG Luminex immunoassay, at 2, 3.5, and 4-to-5 years after the last dose of QHPV in each treatment arm. Results At 4-to-5 years after the last dose of QHPV, antibody titers were significantly higher in 4-dose than in 3-dose group. However, the proportion of vaccinees with a seroresponse in the cLIA assay was not different between the two groups (86–93% for HPV types 6, 11, and 16, and 64% for HPV type 18). These results were very similar to the seroresponse rate in these HIV-infected children at 1 month after completing vaccination. Conclusions Children with well-controlled HIV infection who receive 3 doses of the QHPV vaccine maintain seropositivity and antibody levels that are generally similar to children of the same age who are not HIV-infected. Antibody titer correlated strongly with low log HIV RNA, low CD8%, and high CD4%. Additionally, a fourth dose of vaccine in HIV-infected children produces a marked rise in antibody characteristic of an anamnestic response and persistence of high antibody levels. Study identification: IMPAACT P1085 (V501-021). CLINICALTRIALS.GOV identifier: NCT01206556 .
- Published
- 2017
13. Control vaccine formulation – Authors' reply
- Author
-
Nubia Muñoz and Alfred J. Saah
- Subjects
Societies, Scientific ,Clinical Trials as Topic ,medicine.medical_specialty ,business.industry ,Drug Compounding ,MEDLINE ,Aluminum Hydroxide ,General Medicine ,Phosphates ,Placebos ,medicine ,Humans ,Papillomavirus Vaccines ,Vaccines, Combined ,Intensive care medicine ,Control (linguistics) ,business - Published
- 2021
14. Use of real-world data for HPV vaccine trial follow-up in the Nordic region
- Author
-
Suzanne Campbell, Christian Munk, Laufey Tryggvadottir, Maria Hortlund, Alfred J. Saah, Sophie Berger, Mari Nygård, Susanne K. Kjaer, Espen Enerly, Karin Sundström, and Amita Joshi
- Subjects
Adult ,medicine.medical_specialty ,Adolescent ,Uterine Cervical Neoplasms ,Scandinavian and Nordic Countries ,Clinical study ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,Product Surveillance, Postmarketing ,Humans ,Medicine ,Pharmacology (medical) ,Registries ,030212 general & internal medicine ,Human papillomavirus ,National health ,030505 public health ,Hpv types ,business.industry ,Papillomavirus Infections ,Vaccine trial ,General Medicine ,Biobank ,Vaccination ,Family medicine ,Female ,0305 other medical science ,business ,Real world data ,Follow-Up Studies - Abstract
Post-marketing studies are commonly performed to follow-up on the safety and effectiveness of a drug or vaccine after approval has been obtained. These post-marketing studies may involve the collection of real-world data from registries and clinical biobanks in order to obtain real-world evidence. As this approach can monitor the effects of pharmaceutical products over decades, it is particularly necessary for the development of safe and effective vaccines. A long-term follow-up (LTFU) study was initiated as an extension of a phase 3 clinical study (V501–015; NCT00092534) to assess the effectiveness, immunogenicity and safety of the quadrivalent human papillomavirus (qHPV) vaccine for up to 14 years after the start of vaccination. The LTFU study included participants from Denmark, Iceland, Norway, and Sweden, and assessed qHPV vaccine effectiveness against cervical pre-cancers and cancers caused by the oncogenic HPV types 16 and 18. In particular, our study utilized Nordic national health registries, in which individual patient records were linked by a unique Personal Identity Number. Here, we describe the overall implementation and methodology of the qHPV vaccine LTFU study conducted in the Nordic region. The LTFU study format we describe here supported a comprehensive follow-up process, with near-complete retrieval of registry data and specimens from local laboratories achieved in a timely manner; therefore, we have demonstrated that such a collection is feasible and can be used to address stringent post-marketing requirements.
- Published
- 2020
15. Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age
- Author
-
Dorothy J. Wiley, Suzanne M. Garland, Joaquín Luna, Anna R. Giuliano, Punnee Pitisuttihum, F. Xavier Bosch, Cosette M. Wheeler, Mauricio Hernández-Ávila, Monika Wagner, Jorma Paavonen, Elmar A. Joura, Christine Velicer, N Muñoz, Alain Luxembourg, Alfred J. Saah, Xavier Castellsagué, Susanne K. Kjaer, Se Li, Alex Ferenczy, Daron Gale Ferris, Warner K. Huh, Darron R. Brown, Robert J. Kurman, Kevin A. Ault, Gonzalo Perez, Marc Steben, Joseph Monsonego, Ole Erik Iversen, Brigitte M. Ronnett, Mark H. Stoler, and Mark J. DiNubile
- Subjects
Adult ,medicine.medical_specialty ,Vaginal Neoplasms ,Adolescent ,Genotype ,Uterine Cervical Neoplasms ,Vaginal neoplasm ,Cervical intraepithelial neoplasia ,Vulva ,Placebos ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,medicine ,Humans ,030212 general & internal medicine ,Papillomavirus Vaccines ,Papillomaviridae ,Vulvar neoplasm ,Gynecology ,Vaginal cancer ,integumentary system ,biology ,Vulvar Neoplasms ,business.industry ,Papillomavirus Infections ,Obstetrics and Gynecology ,Vulvar cancer ,biology.organism_classification ,medicine.disease ,Vulvar intraepithelial neoplasia ,female genital diseases and pregnancy complications ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Female ,business ,Carcinoma in Situ - Abstract
To estimate the proportion of vulvar and vaginal low-grade and high-grade squamous intraepithelial lesions (LSILs and HSILs) in females 15-26 years of age attributable to 14 human papillomavirus (HPV) genotypes (6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59).A post hoc analysis of prospectively diagnosed vulvar and vaginal LSILs and HSILs among females 15-26 years of age enrolled in the placebo arms of two phase 3, randomized HPV vaccine trials assessed 14 prespecified HPV genotypes associated with cervical cancers or anogenital warts using a type-specific multiplex polymerase chain reaction assay. The frequency of lesions associated with specific HPV genotypes was estimated by proportional and other attribution methods.During approximately 4 years of follow-up in 8,798 females, 40 vulvar LSILs and 46 vulvar HSILs were diagnosed in 68 females, and 118 vaginal LSILs and 33 vaginal HSILs were diagnosed in 107 females. Females developing vulvar (41.2%) or vaginal (49.5%) lesions also had cervical lesions, whereas 6.5% of females with cervical lesions had vaginal or vulvar lesions. At least 1 of the 14 HPV genotypes was detected in females with vulvar LSIL (72.5%), vulvar HSIL (91.3%), vaginal LSIL (61.9%), and vaginal HSIL (72.7%). Considering only HPV-positive lesions, the nine most common genotypes causing cervical cancer and anogenital warts (6, 11, 16, 18, 31, 33, 45, 52, and 58) were found in 89.4% of vulvar LSILs, 100% of vulvar HSILs, 56.0% of vaginal LSILs, and 78.3% of vaginal HSILs.Most vulvar and vaginal lesions were attributable to at least 1 of the 14 HPV genotypes analyzed. Effective immunization programs could potentially prevent substantial numbers of HPV-related vulvar and vaginal LSILs and HSILs.CLINICALTRIALS.GOV,: NCT00092521 and NCT00092534.
- Published
- 2018
16. High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298
- Author
-
Catherine Godfrey, Elizabeth Y. Chiao, Jennifer Webster-Cyriaque, Robert W. Coombs, Alfred J. Saah, Michelle S. Cespedes, Pawel Paczuski, Joan Dragavon, Ming Yang, Ross D. Cranston, Barbara Bastow, and Timothy J. Wilkin
- Subjects
Microbiology (medical) ,Male ,medicine.medical_specialty ,Phases of clinical research ,Anal Canal ,HIV Infections ,Dermatology ,Placebo ,Article ,Men who have sex with men ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,Internal medicine ,Biopsy ,medicine ,Humans ,030212 general & internal medicine ,Homosexuality, Male ,Papillomaviridae ,medicine.diagnostic_test ,business.industry ,Papillomavirus Infections ,Public Health, Environmental and Occupational Health ,HPV infection ,Cancer ,Anoscopy ,Anal Infection ,Middle Aged ,medicine.disease ,Anus Neoplasms ,CD4 Lymphocyte Count ,Infectious Diseases ,030220 oncology & carcinogenesis ,Female ,Squamous Intraepithelial Lesions of the Cervix ,business - Abstract
Background The quadrivalent human papillomavirus (HPV) vaccine (qHPV; types 6, 11, 16, 18) is indicated for men and women aged 9 to 26 years to prevent HPV associated anogenital high-grade squamous intraepithelial lesions (HSIL) and cancer. ACTG 5298 was a randomized placebo controlled Phase 3 study in human immunodeficiency virus (HIV)-infected men who have sex with men, and women of qHPV to prevent persistent anal HPV infection. Baseline data are presented here. Methods Human immunodeficiency virus-infected men who have sex with men, and women 27 years or older without previous anogenital or oral cancer were enrolled. Baseline anal cytology, high-resolution anoscopy and collection of anal, oral, and vaginal specimens for HPV genotyping were performed and acceptability assessed. Results Five hundred seventy-five (575) participants were enrolled (82% men and 18% women). Median age was 47 years. Race/ethnicity was 46% white, 31% black, and 20% Hispanic. Plasma HIV-1 RNA was less than 50 copies/mL in 83% and median CD4 T count was 602 cells/μL. Abnormal anal cytology was detected in 62%, with corresponding HSIL on biopsy (bHSIL) in 33%. Anal HPV 6, 11, 16, and 18 were detected in 25%, 13%, 32%, and 18% of the participants, respectively. Prevalence of 0, 1, 2, 3, and 4 qHPV types was 40%, 38%, 17%, 4%, and 1%, respectively. Oral infection with 1 or more qHPV type was detected in 10% of the participants. Study procedures were generally acceptable. Conclusions At study baseline, there was a high prevalence of abnormal anal cytology, bHSIL, and HPV infection. Sixty percent of the participants had anal infection with preventable qHPV types.
- Published
- 2018
17. A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men
- Author
-
Mark H. Einstein, Shelly Lensing, J. S. Logan, Joel M. Palefsky, Ronald T. Mitsuyasu, C. B. Ogilvie, J. M. Berry-Lawhorn, Grant B Ellsworth, Jeannette Y. Lee, Timothy J. Wilkin, David M. Aboulafia, Alfred J. Saah, Elizabeth A. Stier, Naomi Jay, and Stephen E. Goldstone
- Subjects
0301 basic medicine ,Adult ,Male ,Population ,HIV Infections ,Antibodies, Viral ,Antibodies ,Human Papillomavirus Recombinant Vaccine Quadrivalent ,Article ,Genital warts ,03 medical and health sciences ,0302 clinical medicine ,Antigen ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,Immunity ,Virology ,Medicine ,Anal cancer ,Humans ,030212 general & internal medicine ,Viral ,education ,Neutralizing ,education.field_of_study ,business.industry ,Immunogenicity ,Papillomavirus Infections ,Antibody titer ,virus diseases ,Middle Aged ,medicine.disease ,030112 virology ,Antibodies, Neutralizing ,3. Good health ,Vaccination ,Infectious Diseases ,Good Health and Well Being ,Immunology ,Types 6 ,business ,Immunologic Memory - Abstract
Persistent infection of the anus with high-risk types of human papillomavirus (HPV) causes squamous cell carcinoma, one of the most common non-AIDS-defining cancers [1], [2]. HIV-infected individuals are at much higher risk for developing anal cancer than HIV-uninfected individuals [3], [4], [5], [6]. Approximately 70% of anal cancers are due to HPV types 16 or 18 and most genital warts are associated with HPV types 6 and 11 [7], [8]. The quadrivalent HPV (qHPV) vaccine, which induces neutralizing antibodies titers in recipients against HPV types 6, 11, 16, and 18, prevented 93% of persistent anal infections and 78% of anal squamous intraepithelial lesions caused by these types in HIV-uninfected men who have sex with men (MSM) [9]. While the qHPV vaccine series is highly immunogenic in HIV-infected adults and children, antibody titers are lower than those reported in HIV-uninfected populations [10], [11], [12]. In studies of both HIV infected and HIV-uninfected vaccine recipients, the titers developed in response to the standard three-dose qHPV series peak soon after the third dose then decline. HIV-uninfected women [13] and HIV-infected children [14] demonstrated an anamnestic response to a fourth dose of the qHPV vaccine suggesting that the qHPV vaccine induces immune memory. Published studies of HIV-infected adults receiving qHPV vaccine have relatively limited follow-up and the characteristics of the long-term humoral response have not yet been described. It is unclear how much immunity wanes in this population and whether the standard 3 dose series generates immune memory which is necessary for long-term protection against new infections. A delayed fourth vaccination can simulate antigen exposure and a robust increase in antibodies suggestive of an anamnestic response indicative of immune memory [13], [14], [15]. When exposed to specific antigens, long-lived memory immune cells generate an immune response to prevent or stop infection [13]. The AIDS Malignancy Consortium Protocol 052 (AMC052) demonstrated the safety and immunogenicity of the standard three dose qHPV vaccine series in HIV-infected adult males [10]. Here we describe the long-term titers after vaccination in this study population. Since there are no accepted criteria for an anamnestic response, we sought to describe the titers at one and four weeks after a fourth dose, similar to what has been shown in HIV-uninfected women [13]. We hypothesized that titers would be higher four weeks after a fourth dose compared with four weeks after the third dose.
- Published
- 2018
18. 4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years
- Author
-
Jaime Alberto Restrepo, Rudiwilai Samakoses, Daron G. Ferris, Andrea Likos Krick, Jian Li Chu, Ole Erik Iversen, Alfred J. Saah, Archana Chatterjee, Jesper Mehlsen, Amita Joshi, Rituparna Das, Eduardo Lazcano-Ponce, and Stanley L Block
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Population ,Disease ,Placebo ,03 medical and health sciences ,0302 clinical medicine ,030225 pediatrics ,medicine ,Humans ,Papillomavirus Vaccines ,030212 general & internal medicine ,Dosing ,Child ,education ,Adverse effect ,Papillomaviridae ,education.field_of_study ,business.industry ,Papillomavirus Infections ,Vaccination ,Titer ,Regimen ,Pediatrics, Perinatology and Child Health ,Female ,business ,Follow-Up Studies - Abstract
OBJECTIVES: We describe the final 10-year data for the long-term follow-up study of the 4-valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents. METHODS: In the base study (V501-018), 1661 sexually inactive boys and girls received the 4vHPV vaccine (early vaccination group [EVG], managed for 9.9 years) or a placebo at day 1, month 2, and month 6. Thereafter, at month 30, the placebo group (catch-up vaccination group [CVG], managed for 7.4 years) received the 4vHPV vaccine by using the same dosing schedule. Long-term anti-HPV type 6, 11, 16, and 18 immune responses were assessed. Effectiveness was estimated by calculating the incidence rate of the primary endpoints (HPV types 6, 11, 16, and 18–related disease or persistent infection). RESULTS: For HPV types 6, 11, and 16, 89% to 96% of subjects remained seropositive through 10-years postvaccination. The preadolescents had 38% to 65% higher geometric mean titers at month 7, which remained 16% to 42% higher at 10 years compared with adolescents. No cases of HPV type 6, 11, 16, and 18–related diseases were observed. Ten subjects had a persistent infection of ≥6 months duration with vaccine-type HPV and 2 subjects had persistent infection for ≥12 months. No new serious adverse events were reported through 10 years. CONCLUSIONS: A 3-dose regimen of the 4vHPV vaccine was immunogenic, clinically effective, and generally well tolerated in preadolescents and adolescents during 10 years of follow-up. These long-term findings support efforts to vaccinate this population against HPV before exposure.
- Published
- 2017
19. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa
- Author
-
Nelly Mugo, Nana Akosua Ansah, Alfred J. Saah, Deborah Marino, and Elizabeth I.O. Garner
- Subjects
Adult ,Pediatrics ,medicine.medical_specialty ,Sub saharan ,Adolescent ,Drug-Related Side Effects and Adverse Reactions ,Immunology ,Short Report ,Human immunodeficiency virus (HIV) ,Human papillomavirus vaccine ,Antibodies, Viral ,Cervical cancer screening ,medicine.disease_cause ,Placebo ,Ghana ,Placebos ,Young Adult ,Double-Blind Method ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,medicine ,Humans ,Immunology and Allergy ,Child ,Pharmacology ,Cervical cancer ,business.industry ,Immunogenicity ,Papillomavirus Infections ,medicine.disease ,Kenya ,Healthy Volunteers ,Senegal ,Confidence interval ,Treatment Outcome ,Female ,business - Abstract
Due to sporadic and not easily accessible cervical cancer screening, human papillomavirus (HPV)-related cervical cancer is a leading cause of cancer death in Sub-Saharan African women. This study was designed to assess the safety and immunogenicity of a quadrivalent human papillomavirus (qHPV) vaccine in sub-Saharan African women. This seven month, double-blind study enrolled 250 healthy, human immunodeficiency virus (HIV)-uninfected females ages 9-26 residing in Ghana, Kenya, and Senegal. Thirty females ages 13-15 and 120 females ages 16-26 received qHPV vaccine. In addition, 100 females ages 9-12 y were randomized in a 4:1 ratio to receive either qHPV vaccine (n = 80) or placebo (n = 20 ). The primary immunogenicity hypothesis was that an acceptable percentage of subjects who received the qHPV vaccine seroconvert to HPV6/11/16/18 at 4 weeks post-dose 3, defined as the lower bound of the corresponding 95% confidence interval (CI) exceeding 90%. The primary safety objective was to demonstrate that qHPV vaccine was generally well tolerated when administered in a 3-dose regimen. The pre-specified statistical criterion for the primary immunogenicity hypothesis was met: the lower bound of the 95% exact binomial CI on the seroconversion rate was at least 98% for each vaccine HPV type and all subjects seroconverted by 4 weeks post-dose 3. Across vaccination groups, the most common adverse events (AE) were at the injection site, including pain, swelling, and erythema. No subject discontinued study medication due to an AE and no serious AEs were reported. There were no deaths. This study demonstrated that qHPV vaccination of sub-Saharan African women was highly immunogenic and generally well tolerated.
- Published
- 2015
20. Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease
- Author
-
Mauricio Hernández-Ávila, Christine Velicer, Nubia Muñoz, Cosette M. Wheeler, Darron R. Brown, Heather L. Sings, Kevin A. Ault, Jack Cuzick, Alain Luxembourg, Susanne K. Kjaer, Joseph Monsonego, Alfred J. Saah, F. Xavier Bosch, Joaquín Luna, Punnee Pitisuttithum, Suzanne M. Garland, Anna R. Giuliano, Elmar A. Joura, Jorma Paavonen, Dianne Miller, Ole Erik Iversen, Daron G. Ferris, Marc Steben, Gonzalo Perez, Evan R. Myers, and Warner K. Huh
- Subjects
Papillomavirus vaccines ,Epidemiology ,Uterine cervix adenocarcinoma ,Uterine Cervical Neoplasms ,Alphapapillomavirus ,Genital warts ,Human papillomavirus type 18 ,Human papillomavirus type 6 ,Risk Factors ,Human papillomavirus type 58 ,Phase 3 clinical trial ,Infection prevention ,Human papillomavirus type 16 ,Uterine cervix carcinoma in situ ,Human papillomavirus type 59 ,Prevalence ,Mixed infection ,Cumulative incidence ,Human papillomavirus type 56 ,Human papillomavirus type 11 ,Papillomaviridae ,Young adult ,Drug safety ,Middle aged ,Human papillomavirus type 52 ,Human papillomavirus type 51 ,biology ,Incidence ,Incidence (epidemiology) ,Vaccination ,Double blind procedure ,Middle Aged ,Papanicolaou test ,female genital diseases and pregnancy complications ,Algorithm ,Oncology ,Randomized controlled trial ,Female ,Uterine cervix cancer ,Human ,Adult ,medicine.medical_specialty ,Uterine cervical neoplasms ,Adolescent ,Genotype ,Uterine cervix biopsy ,Double-blind method ,Groups by age ,Major clinical study ,Adenocarcinoma ,Papillomavirus infection ,Persistent infection ,Uterine cervix cytology ,Cervical intraepithelial neoplasia ,Article ,Papillomavirus infections ,Young Adult ,Human papillomavirus type 39 ,Double-Blind Method ,Human papillomavirus type 35 ,Virology ,Internal medicine ,Genetics ,medicine ,Humans ,Human papillomavirus type 31 ,Papillomavirus Vaccines ,Human papillomavirus type 33 ,Human tissue ,Risk factor ,Placebo ,business.industry ,Papillomavirus Infections ,Follow up ,Uterine Cervical Dysplasia ,Nonhuman ,biology.organism_classification ,medicine.disease ,High risk patient ,Surgery ,Drug efficacy ,Risk factors ,Human papillomavirus type 45 ,business ,Wart virus vaccine ,Controlled study - Abstract
Background: We estimated the prevalence and incidence of 14 human papillomavirus (HPV) types (6/11/16/18/31/33/35/39/45/51/52/56/58/59) in cervicovaginal swabs, and the attribution of these HPV types in cervical intraepithelial neoplasia (CIN), and adenocarcinoma in situ (AIS), using predefined algorithms that adjusted for multiple-type infected lesions. Methods: A total of 10,656 women ages 15 to 26 years and 1,858 women ages 24 to 45 years were enrolled in the placebo arms of one of three clinical trials of a quadrivalent HPV vaccine. We estimated the cumulative incidence of persistent infection and the proportion of CIN/AIS attributable to individual carcinogenic HPV genotypes, as well as the proportion of CIN/AIS lesions potentially preventable by a prophylactic 9-valent HPV6/11/16/18/31/33/45/52/58 vaccine. Results: The cumulative incidence of persistent infection with ≥1 of the seven high-risk types included in the 9-valent vaccine was 29%, 12%, and 6% for women ages 15 to 26, 24 to 34, and 35 to 45 years, respectively. A total of 2,507 lesions were diagnosed as CIN or AIS by an expert pathology panel. After adjusting for multiple-type infected lesions, among women ages 15 to 45 years, these seven high-risk types were attributed to 43% to 55% of CIN1, 70% to 78% of CIN2, 85% to 91% of CIN3, and 95% to 100% of AIS lesions, respectively. The other tested types (HPV35/39/51/56/59) were attributed to 23% to 30% of CIN1, 7% to 14% of CIN2, 3% to 4% of CIN3, and 0% of AIS lesions, respectively. Conclusions: Approximately 85% or more of CIN3/AIS, >70% CIN2, and approximately 50% of CIN1 lesions worldwide are attributed to HPV6/11/16/18/31/33/45/52/58. Impact: If 9-valent HPV vaccination programs are effectively implemented, the majority of CIN2 and CIN3 lesions worldwide could be prevented, in addition to approximately one-half of CIN1. Cancer Epidemiol Biomarkers Prev; 23(10); 1997–2008. ©2014 AACR.
- Published
- 2014
21. A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries
- Author
-
Amita Joshi, Lara G. Sigurdardottir, Bo T. Hansen, Maria Hortlund, David Radley, Rituparna Das, Laufey Tryggvadottir, J. Brooke Marshall, Joakim Dillner, Susanne K. Kjaer, Christian Munk, Meng Li, Mari Nygård, and Alfred J. Saah
- Subjects
Microbiology (medical) ,Adult ,Pediatrics ,medicine.medical_specialty ,Time Factors ,Denmark ,Population ,Human Papilloma Virus Vaccine ,Prevalence ,Iceland ,Uterine Cervical Neoplasms ,Adenocarcinoma in Situ ,Cervical intraepithelial neoplasia ,Cohort Studies ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,Risk Factors ,030225 pediatrics ,medicine ,Humans ,030212 general & internal medicine ,education ,Vaccine Potency ,Cervical cancer ,Sweden ,education.field_of_study ,Human papillomavirus 16 ,Human papillomavirus 18 ,business.industry ,Norway ,Incidence (epidemiology) ,Papillomavirus Infections ,Vaccination ,medicine.disease ,Uterine Cervical Dysplasia ,female genital diseases and pregnancy complications ,Regimen ,Infectious Diseases ,Cohort ,Female ,business ,Follow-Up Studies - Abstract
Background The long-term effectiveness of the quadrivalent human papillomavirus (qHPV) vaccine was assessed by monitoring the combined incidence of cervical intraepithelial neoplasia (CIN2, CIN3), adenocarcinoma in situ (AIS), and cervical cancer related to HPV16 or HPV18. Methods Women from Nordic countries of Denmark, Iceland, Norway, and Sweden who received a 3-dose regimen of the qHPV vaccine in the beginning of FUTURE II (Females United to Unilaterally Reduce Endo/Ectocervical Disease; V501-015, base study NCT00092534) are followed through different national registries. Effectiveness analyses were conducted approximately 2 years following completion of the base study and occur approximately every 2 years thereafter for 10 years (ie, 14 years from day 1 of the base study). Vaccine effectiveness against HPV16/18-related CIN2 or worse (CIN2+) was estimated by comparing the observed incidence with the expected incidence of CIN2+ in an unvaccinated cohort using historical registry data. Results In the per-protocol population (2084 women) analysis of effectiveness after the first 12 years, there were no breakthrough cases of HPV16/18 CIN2+ after 9437 person- years of follow-up. Statistical power was sufficient to conclude that qHPV vaccine effectiveness remains above 90% for at least 10 years. The number of person-years during the follow-up interval of 10-12 years is continuing to accrue and shows a trend toward continuing effectiveness of the vaccine during that period. Conclusion The qHPV vaccine shows continued protection in women through at least 10 years, with a trend for continued protection through 12 years of follow-up. Clinical trials registration NCT00092534. Study identification V501-015.
- Published
- 2016
22. High-Grade Anal Intraepithelial Neoplasia Among HIV-1-Infected Men Screening for a Multicenter Clinical Trial of a Human Papillomavirus Vaccine
- Author
-
David M. Aboulafia, Jeannette Y. Lee, Elizabeth A. Stier, Ronald T. Mitsuyasu, Shelly Lensing, Mark H. Einstein, Michael J. Berry, Alfred J. Saah, Joel M. Palefsky, Naomi Jay, Timothy J. Wilkin, and Stephen E. Goldstone
- Subjects
Male ,Cervical Cancer ,Gastroenterology ,Cytology ,Pharmacology (medical) ,human papillomavirus ,Cancer ,Human papillomavirus 16 ,medicine.diagnostic_test ,Vaccination ,anal infection ,virus diseases ,Middle Aged ,Anal Infection ,Anus Neoplasms ,Infectious Diseases ,HIV/AIDS ,Infection ,Carcinoma in Situ ,Adult ,medicine.medical_specialty ,Clinical Trials and Supportive Activities ,Clinical Sciences ,HIV-1 infection ,Article ,Vaccine Related ,anal intraepithelial neoplasia ,Clinical Research ,Virology ,Internal medicine ,medicine ,Humans ,Anal cancer ,Papillomavirus Vaccines ,Human papillomavirus ,Gynecology ,Acquired Immunodeficiency Syndrome ,business.industry ,Prevention ,Anal intraepithelial neoplasia ,Anoscopy ,medicine.disease ,CD4 Lymphocyte Count ,Clinical trial ,Good Health and Well Being ,HIV-1 ,Sexually Transmitted Infections ,Immunization ,Digestive Diseases ,business - Abstract
Purpose: High-grade anal intraepithelial neoplasia (HGAIN) is the precursor lesion to invasive anal cancer. Human papillomavirus (HPV) vaccination holds great promise for preventing anal cancer. Methods: We examined 235 HIV-1-infected men screening for participation in a multisite clinical trial of a quadrivalent HPV vaccine. All participants had anal swabs obtained for HPV testing and cytology and high-resolution anoscopy with biopsies of visible lesions to assess for HGAIN. Results: HPV types 16 and 18 were detected in 23% and 10%, respectively; abnormal anal cytology was found in 56% and HGAIN in 30%. HGAIN prevalence was significantly higher in those with HPV16 detection compared to those without (38% vs 17%; P = .01). Use of antiretroviral therapy and nadir and current CD4+ cell count were not associated with abnormal anal cytology or HGAIN. Conclusion: HGAIN is highly prevalent in HIV-infected men. Further studies are needed on treatment and prevention of HGAIN.
- Published
- 2013
23. Impact and effectiveness of the quadrivalent human papillomavirus vaccine:A systematic review of 10 years of real-world experience
- Author
-
Rosybel Drury, Christine Velicer, Stan L. Block, Gonzalo Perez, Alfred J. Saah, Darron R. Brown, Rituparna Das, Géraldine Dominiak-Felden, Barbara J. Kuter, Brianna Lindsay, Mark J. DiNubile, Suzanne M. Garland, Nubia Muñoz, and Susanne K. Kjaer
- Subjects
Male ,Pediatrics ,cervical cancer ,Drug exposure ,Uterine Cervical Neoplasms ,Gardasil/Silgard ,Disease ,Review ,Genital warts ,Human papillomavirus type 18 ,Human papillomavirus type 6 ,0302 clinical medicine ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,Observational study ,Medicine ,030212 general & internal medicine ,Human papillomavirus type 11 ,CIN ,Review Articles ,Papillomaviridae ,Priority journal ,Cervical cancer ,Embase ,Vaccination ,HPV infection ,Condyloma acuminatum ,Medline ,virus diseases ,female genital diseases and pregnancy complications ,Precancer ,Infectious Diseases ,Condylomata Acuminata ,030220 oncology & carcinogenesis ,Female ,Uterine cervix cancer ,Developed country ,genital warts ,Human ,Microbiology (medical) ,medicine.medical_specialty ,Immunology ,Human Papilloma Virus Vaccine ,Histopathology ,Papillomavirus infection ,Uterine cervix cytology ,03 medical and health sciences ,Virology ,Humans ,HPV vaccination ,business.industry ,Public health ,Papillomavirus Infections ,medicine.disease ,Clinical effectiveness ,Systematic review ,business ,Uterine cervix tumor ,Wart virus vaccine - Abstract
This systematic review assessed the global impact and effectiveness of quadrivalent human papillomavirus (HPV) vaccination on HPV infection and disease in real-world settings over a decade of use. Substantial reductions in HPV 6/11/16/18 infection, anogenital warts, and cervical lesions have been achieved., Prophylactic human papillomavirus (HPV) vaccination programs constitute major public health initiatives worldwide. We assessed the global effect of quadrivalent HPV (4vHPV) vaccination on HPV infection and disease. PubMed and Embase were systematically searched for peer-reviewed articles from January 2007 through February 2016 to identify observational studies reporting the impact or effectiveness of 4vHPV vaccination on infection, anogenital warts, and cervical cancer or precancerous lesions. Over the last decade, the impact of HPV vaccination in real-world settings has become increasingly evident, especially among girls vaccinated before HPV exposure in countries with high vaccine uptake. Maximal reductions of approximately 90% for HPV 6/11/16/18 infection, approximately 90% for genital warts, approximately 45% for low-grade cytological cervical abnormalities, and approximately 85% for high-grade histologically proven cervical abnormalities have been reported. The full public health potential of HPV vaccination is not yet realized. HPV-related disease remains a significant source of morbidity and mortality in developing and developed nations, underscoring the need for HPV vaccination programs with high population coverage.
- Published
- 2016
24. Mother-Infant Transfer of Anti-Human Papillomavirus (HPV) Antibodies following Vaccination with the Quadrivalent HPV (Type 6/11/16/18) Virus-Like Particle Vaccine
- Author
-
Ricardo Manalastas, Katie Matys, Oliver Bautista, Sara Mallary, Alfred J. Saah, Punee Pitisuttithum, and Scott Vuocolo
- Subjects
Adult ,Microbiology (medical) ,Philippines ,Clinical Biochemistry ,Immunology ,Antibodies, Viral ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,Pregnancy ,medicine ,Humans ,Immunology and Allergy ,Papillomavirus Vaccines ,Vaccines ,biology ,business.industry ,Immunogenicity ,Infant, Newborn ,HPV infection ,Infant ,Middle Aged ,Fetal Blood ,Thailand ,medicine.disease ,Virology ,female genital diseases and pregnancy complications ,Vaccines, Virosome ,Vaccination ,Titer ,Immunoglobulin G ,Cord blood ,biology.protein ,Female ,Antibody ,Recurrent Respiratory Papillomatosis ,business ,Immunity, Maternally-Acquired - Abstract
The exploratory immunogenicity objective of this analysis was to characterize the titer of vaccine human papillomavirus (HPV)-type immunoglobulins in both peripartum maternal blood and the cord blood of infants born to women who received blinded therapy. Data were derived from a randomized, placebo-controlled, double-blind safety, immunogenicity, and efficacy study (protocol 019; NCT00090220). This study enrolled 3,819 women between the ages of 24 and 45 years from 38 international study sites between 18 June 2004 and 30 April 2005. Data in the current analysis are from subjects enrolled in Philippines and Thailand. For each of HPV types 6, 11, 16, and 18, maternal anti-HPV was found in cord blood samples. Furthermore, HPV titers in cord blood samples were highly positively correlated with maternal HPV titers. Additionally, there were instances when anti-HPV antibodies were no longer detectable in maternal serum samples and yet were detected in matched cord blood samples. These results demonstrate that quadrivalent HPV (qHPV) vaccine-induced antibodies cross the placenta and could potentially provide some benefit against vaccine-type HPV infection and related diseases such as recurrent respiratory papillomatosis.
- Published
- 2012
25. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women
- Author
-
Abdul Ghani Nur Azurah, Maria Jose Miranda, Kyung Hyo Kim, Mehmet Ceyhan, Vladimir Dvorak, Stan L. Block, Kulkanya Chokephaibulkit, Ole Erik Iversen, Angels Ulied, Alain Luxembourg, Ramon M. Cestero, Matitiahu Berkovitch, Siew Moy Fong, Erica Lazarus, Misoo C. Ellison, Ales Skrivanek, Alfred J. Saah, Shuai S. Yuan, Mark J. DiNubile, Terje Soerdal, and Michael Ritter
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Time Factors ,Adolescent ,Genotype ,Human Papilloma Virus Vaccine ,Psychological intervention ,Genital warts ,Cohort Studies ,Young Adult ,03 medical and health sciences ,Immunogenicity, Vaccine ,Sex Factors ,0302 clinical medicine ,Ambulatory care ,Antibody Specificity ,030225 pediatrics ,medicine ,Clinical endpoint ,Humans ,Papillomavirus Vaccines ,030212 general & internal medicine ,Young adult ,Child ,Papillomaviridae ,Immunization Schedule ,Gynecology ,Cervical cancer ,Hpv types ,business.industry ,Immunogenicity ,Papillomavirus Infections ,Age Factors ,Obstetrics and Gynecology ,General Medicine ,medicine.disease ,Vaccination ,Regimen ,Elder Nutritional Physiological Phenomena ,030220 oncology & carcinogenesis ,Cohort ,Female ,business ,Cohort study - Abstract
Human papillomavirus (HPV) infections cause anogenital cancers and warts. The 9-valent HPV vaccine provides protection against 7 high-risk types of HPV responsible for 90% of cervical cancers and 2 other HPV types accounting for 90% of genital warts.To determine whether HPV type-specific antibody responses would be noninferior among girls and boys aged 9 to 14 years after receiving 2 doses of the 9-valent HPV vaccine compared with adolescent girls and young women aged 16 to 26 years receiving 3 doses.Open-label, noninferiority, immunogenicity trial conducted at 52 ambulatory care sites in 15 countries. The study was initiated on December 16, 2013, with the last participant visit for this report on June 19, 2015. Five cohorts were enrolled: (1) girls aged 9 to 14 years to receive 2 doses 6 months apart (n = 301); (2) boys aged 9 to 14 years to receive 2 doses 6 months apart (n = 301); (3) girls and boys aged 9 to 14 years to receive 2 doses 12 months apart (n = 301); (4) girls aged 9 to 14 years to receive 3 doses over 6 months (n = 301); and (5) a control group of adolescent girls and young women aged 16 to 26 years to receive 3 doses over 6 months (n = 314).Two doses of the 9-valent HPV vaccine administered 6 or 12 months apart or 3 doses administered over 6 months.The primary end point was prespecified as the antibody response against each HPV type assessed 1 month after the last dose using a competitive immunoassay. Each of the three 2-dose regimens was compared with the standard 3-dose schedule in adolescent girls and young women using a noninferiority margin of 0.67 for the ratio of the antibody geometric mean titers.Of the 1518 participants (753 girls [mean age, 11.4 years]; 451 boys [mean age, 11.5 years]; and 314 adolescent girls and young women [mean age, 21.0 years]), 1474 completed the study and data from 1377 were analyzed. At 4 weeks after the last dose, HPV antibody responses in girls and boys given 2 doses were noninferior to HPV antibody responses in adolescent girls and young women given 3 doses (P .001 for each HPV type). Compared with adolescent girls and young women who received 3 doses over 6 months, the 1-sided 97.5% CIs for the ratio of HPV antibody geometric mean titers at 1 month after the last dose across the 9 HPV subtypes ranged from 1.36 to ∞ to 2.50 to ∞ for girls who received 2 doses 6 months apart; from 1.37 to ∞ to 2.55 to ∞ for boys who received 2 doses 6 months apart; and from 1.61 to ∞ to 5.36 to ∞ for girls and boys who received 2 doses 12 months apart.Among girls and boys aged 9 to 14 years receiving 2-dose regimens of a 9-valent HPV vaccine separated by 6 or 12 months, immunogenicity 4 weeks after the last dose was noninferior to a 3-dose regimen in a cohort of adolescent girls and young women. Further research is needed to assess persistence of antibody responses and effects on clinical outcomes.clinicaltrials.gov Identifier: NCT01984697.
- Published
- 2017
26. Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV‐1–Infected Men
- Author
-
Alfred J. Saah, Ronald T. Mitsuyasu, Elizabeth A. Stier, Mark H. Einstein, J. Michael Berry, David M. Aboulafia, Shelly Lensing, Timothy J. Wilkin, Stephen E. Goldstone, David L. Cohn, Naomi Jay, Joel M. Palefsky, and Jeannette Y. Lee
- Subjects
Adult ,Male ,medicine.medical_specialty ,Human Papilloma Virus Vaccine ,Anal Canal ,HIV Infections ,Antibodies, Viral ,Article ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,Acquired immunodeficiency syndrome (AIDS) ,Internal medicine ,medicine ,Humans ,Immunology and Allergy ,Anal cancer ,Papillomavirus Vaccines ,Seroconversion ,Adverse effect ,business.industry ,Middle Aged ,Anal canal ,Anal Infection ,Anus Neoplasms ,medicine.disease ,Vaccination ,Infectious Diseases ,medicine.anatomical_structure ,Immunology ,HIV-1 ,business - Abstract
Background Human immunodeficiency virus type 1 (HIV-1)-infected men are at increased risk for anal cancer. Human papillomavirus (HPV) vaccination may prevent anal cancer caused by vaccine types. Methods AIDS Malignancy Consortium Protocol 052 is a single-arm, open-label, multicenter clinical trial to assess the safety and immunogenicity of the quadrivalent HPV (types 6, 11, 16, and 18) vaccine in HIV-1-infected men. Men with high-grade anal intraepithelial neoplasia or anal cancer by history or by screening cytology or histology were excluded. Men received 0.5 mL intramuscularly at entry, week 8, and week 24. The primary end points were seroconversion to vaccine types at week 28, in men who were seronegative and without anal infection with the relevant HPV type at entry, and grade 3 or higher adverse events related to vaccination. Results There were no grade 3 or greater adverse events attributable to vaccination among the 109 men who received at least 1 vaccine dose. Seroconversion was observed for all 4 types: type 6 (59 [98%] of 60), type 11 (67 [99%] of 68), type 16 (62 [100%] of 62), and type 18 (74 [95%] of 78). No adverse effects on CD4 counts and plasma HIV-1 RNA levels were observed. Conclusions The quadrivalent HPV vaccine appears safe and highly immunogenic in HIV-1-infected men. Efficacy studies in HIV-1-infected men are warranted. Clinical trials registration. NCT 00513526.
- Published
- 2010
27. Association between pap abnormalities and HPV infection in participants in HPV vaccine clinical trials
- Author
-
Christine Velicer, Alain Luxembourg, Alfred J. Saah, and Evan R. Meyers
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Hpv types ,business.industry ,HPV infection ,virus diseases ,HPV vaccines ,medicine.disease ,female genital diseases and pregnancy complications ,Clinical trial ,Internal medicine ,medicine ,business - Abstract
5530Background: Few studies have reported the burden of Pap abnormalities associated with the specific HPV types targeted by HPV vaccines. The purpose of this analysis is to estimate prevalence of ...
- Published
- 2018
28. Pregnancy and Infant Outcomes in the Clinical Trials of a Human Papillomavirus Type 6/11/16/18 Vaccine
- Author
-
Heather L. Sings, David Radley, Suzanne M. Garland, Karen L. Ciprero, Deborah Marino, Haiping Zhou, Stanley A. Gall, Jorma Paavonen, Desmond Ryan, Alfred J. Saah, Richard M. Haupt, Elizabeth I.O. Garner, and Kevin A. Ault
- Subjects
Adult ,medicine.medical_specialty ,Pediatrics ,Randomization ,Adolescent ,Infant, Newborn, Diseases ,law.invention ,Young Adult ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,Obstetrics and gynaecology ,Randomized controlled trial ,Pregnancy ,law ,Epidemiology ,medicine ,Humans ,Lactation ,Papillomavirus Vaccines ,Young adult ,Adverse effect ,Randomized Controlled Trials as Topic ,Gynecology ,business.industry ,Infant, Newborn ,Pregnancy Outcome ,Obstetrics and Gynecology ,Middle Aged ,medicine.disease ,Clinical trial ,Clinical Trials, Phase III as Topic ,Female ,business - Abstract
To present a combined analysis of the pregnancy outcomes for women aged up to 45 years enrolled in five phase III clinical studies of the prophylactic quadrivalent human papillomavirus 6/11/16/18 vaccine.Twenty thousand five hundred fifty-one women aged 15-45 years received quadrivalent HPV vaccine or placebo at day 1 and months 2 and 6. Urine pregnancy tests were performed immediately before each injection; participants testing positive were not vaccinated. Women who became pregnant after enrollment were discontinued from further vaccination until resolution of pregnancy. All pregnancies were followed for outcomes.During the studies, 1,796 vaccine and 1,824 placebo recipients became pregnant, resulting in 2,008 and 2,029 pregnancies with known outcomes. No significant differences were noted overall for the proportions of pregnancies resulting in live birth, fetal loss, or spontaneous abortion. A total of 40 neonates born to vaccinated women and 30 neonates born to women given placebo had one or more congenital anomalies (P=.20). The anomalies were diverse and consistent with those most commonly observed in the general population. The vaccine was well tolerated among women who became pregnant.Administration of quadrivalent human papillomavirus vaccine to women who became pregnant during the phase III clinical trials did not appear to negatively affect pregnancy outcomes. The vaccine is a U.S. Food and Drug Administration pregnancy category B medication (animal studies revealed no evidence of fetal harm, but there are no adequate and well-controlled studies in pregnant women); however, vaccination is not recommended during pregnancy. Postlicensure surveillance is ongoing.ClinicalTrials.gov, www.clinicaltrials.gov, NCT00092521, NCT00092534, NCT00092495, NCT00092547 and NCT00090220.II.
- Published
- 2009
29. Prevalence and Incidence of HPV Genital Infection in Women
- Author
-
Xingshu Zhu, Christine Velicer, Scott Vuocolo, Kai-Li Liaw, and Alfred J. Saah
- Subjects
Adult ,Microbiology (medical) ,medicine.medical_specialty ,Philippines ,Population ,Gonorrhea ,Prevalence ,Dermatology ,Colombia ,Double-Blind Method ,Risk Factors ,Seroepidemiologic Studies ,Internal medicine ,Humans ,Multicenter Studies as Topic ,Medicine ,Papillomavirus Vaccines ,Prospective Studies ,education ,Randomized Controlled Trials as Topic ,Anus Diseases ,education.field_of_study ,Chlamydia ,business.industry ,Incidence ,Incidence (epidemiology) ,Papillomavirus Infections ,Vaccination ,Public Health, Environmental and Occupational Health ,HPV infection ,Sexually Transmitted Diseases, Viral ,Middle Aged ,Thailand ,medicine.disease ,Vaccine efficacy ,United States ,Europe ,Treatment Outcome ,Infectious Diseases ,Immunology ,Female ,business - Abstract
BACKGROUND: A prophylactic quadrivalent human papillomavirus (HPV) vaccine could benefit adult women if they are susceptible to incident genital HPV infections and are acquiring new infections with vaccine HPV types to which they were previously not exposed. This report presents baseline and prospective data from a randomized double-blind placebo-controlled trial of the safety immunogenicity and efficacy of the quadrivalent HPV (Type 6/11/16/18) vaccine in women ages 24 to 45. METHODS: We present the results of an epidemiologic analysis of 3730 women enrolled in a quadrivalent HPV vaccine efficacy trial between June 18 2004 and April 30 2008. Subjects were enrolled from 7 countries (Colombia France Germany Philippines Spain Thailand and the United States) through community and academic health centers and primary health care providers. RESULTS: Average baseline prevalence of anogenital infection and/or seropositivity was 32.8% for >or=1 vaccine HPV types and 0.3% for all vaccine HPV types. Incidence of anogential infection with any vaccine HPV type was approximately 10.5%. The rate of persistent infection was approximately 5% over a 30-month period among women in the placebo arm naive to the relevant type at baseline. Predictors of incident infection included younger age marital status other than first marriage higher number of lifetime and recent sex partners and Chlamydia/gonorrhea infection at baseline. CONCLUSIONS: These findings indicate that women up to age 45 are susceptible to vaccine HPV types and some are acquiring anogenital infections with vaccine HPV types. Future study concerning incident and prevalent HPV infection among women up to age 45 is warranted (Trial NCT number NCT00090220).
- Published
- 2009
30. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial
- Author
-
Damrong Tresukosol, Frank J. Taddeo, Oliver Bautista, Ricardo Manalastas, Eliav Barr, Evan R. Myers, Joseph Monsonego, Punee Pitisuttithum, Janine T. Bryan, Scott Vuocolo, Joaquín Luna, Kevin A. Ault, Richard M. Haupt, Sara Hood, Nubia Muñoz, Mark T. Esser, Christine Clavel, and Alfred J. Saah
- Subjects
Adult ,medicine.medical_specialty ,Philippines ,Population ,Uterine Cervical Neoplasms ,Alphapapillomavirus ,Colombia ,Placebo ,Genital warts ,law.invention ,Double-Blind Method ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,Papillomavirus Vaccines ,Adverse effect ,education ,education.field_of_study ,business.industry ,Incidence ,Incidence (epidemiology) ,Papillomavirus Infections ,Vaccination ,Age Factors ,General Medicine ,Middle Aged ,Thailand ,medicine.disease ,United States ,Europe ,Clinical trial ,Immunology ,Female ,Safety ,business ,Follow-Up Studies - Abstract
Summary Background Although the peak incidence of human papillomavirus (HPV) infection occurs in most populations within 5–10 years of first sexual experience, all women remain at risk for acquisition of HPV infections. We tested the safety, immunogenicity, and efficacy of the quadrivalent HPV (types 6, 11, 16, 18) L1 virus-like-particle vaccine in women aged 24–45 years. Methods Women aged 24–45 years with no history of genital warts or cervical disease were enrolled from community health centres, academic health centres, and primary health-care providers into an ongoing multicentre, parallel, randomised, placebo-controlled, double-blind study. Participants were allocated by computer-generated schedule to receive quadrivalent HPV vaccine (n=1911) or placebo (n=1908) at day 1, and months 2 and 6. All study site investigators and personnel, study participants, monitors, and central laboratory personnel were blinded to treatment allocation. Coprimary efficacy endpoints were 6 months' or more duration of infection and cervical and external genital disease due to HPV 6, 11, 16, 18; and due to HPV 16 and 18 alone. Primary efficacy analyses were done in a per-protocol population, but intention-to-treat analyses were also undertaken. This study is registered with ClinicalTrials.gov, number NCT00090220. Findings 1910 women received at least one dose of vaccine and 1907 at least one dose of placebo. In the per-protocol population, efficacy against the first coprimary endpoint (disease or infection related to HPV 6, 11, 16, and 18) was 90·5% (95% CI 73·7–97·5, four of 1615 cases in the vaccine group vs 41/1607 in the placebo group) and 83·1% (50·6–95·8, four of 1601 cases vs 23/1579 cases) against the second coprimary endpoint (disease or infection related to HPV 16 and 18 alone). In the intention-to-treat population, efficacy against the first coprimary endpoint was 30·9% (95% CI 11·1–46·5, 108/1886 cases vs 154/1883 cases) and against the second coprimary endpoint was 22·6% (−2·9 to 41·9, 90/1886 cases vs 115/1883 cases), since infection and disease were present at baseline. We recorded no vaccine-related serious adverse events. Interpretation The quadrivalent HPV vaccine is efficacious in women aged 24–45 years not infected with the relevant HPV types at enrolment. Funding Merck (USA).
- Published
- 2009
31. Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease
- Author
-
David Radley, Alfred J. Saah, and Margaret Stanley
- Subjects
0301 basic medicine ,Adult ,medicine.medical_specialty ,Adolescent ,viruses ,Immunology ,Short Report ,HPV vaccines ,Adenocarcinoma ,Cervical intraepithelial neoplasia ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Internal medicine ,medicine ,Immunology and Allergy ,Humans ,Young adult ,neoplasms ,Pharmacology ,Gynecology ,Cervical cancer ,Clinical Trials as Topic ,Human papillomavirus 16 ,integumentary system ,Human papillomavirus 18 ,Surrogate endpoint ,business.industry ,Papillomavirus Infections ,virus diseases ,Odds ratio ,Middle Aged ,medicine.disease ,Uterine Cervical Dysplasia ,female genital diseases and pregnancy complications ,Clinical trial ,030104 developmental biology ,030220 oncology & carcinogenesis ,Chronic Disease ,Uterine Neoplasms ,Female ,business ,Follow-Up Studies - Abstract
We investigated the relationship between high-grade cervical disease (cervical intraepithelial neoplasia [CIN] 2, CIN3 or adenocarcinoma in situ) and persistent infection with HPV16 and/or HPV18 (HPV16/18) among 3970 women who received placebo in 3 clinical trials of a quadrivalent HPV vaccine. Statistical analysis (odds ratios, sensitivity, specificity, negative and positive predictive values, negative and positive likelihood ratios) showed that patients with a persistent infection with HPV16/18 had a much greater risk of HPV16/18-related high-grade cervical disease. Furthermore, subjects without a persistent infection with HPV16/18 were unlikely to have HPV16/18-related high-grade cervical disease. These results suggest that persistent infection with HPV16/18 meets the criteria for a surrogate endpoint for HPV16/18-related high-grade cervical disease and may be used as such in future clinical studies with prophylactic HPV vaccines and in natural history studies.
- Published
- 2015
32. Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine
- Author
-
Christian Munk, Susanne K. Kjaer, Laufey Tryggvadottir, Joakim Dillner, Scott Vuocolo, Alfred J. Saah, Espen Enerly, Mari Nygård, Lara G. Sigurdardottir, and Maria Hortlund
- Subjects
Microbiology (medical) ,Serum ,medicine.medical_specialty ,Time Factors ,Adolescent ,Clinical Biochemistry ,Immunology ,Antibodies, Viral ,Immunoglobulin G ,Young Adult ,Double-Blind Method ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,Internal medicine ,medicine ,Immunology and Allergy ,Humans ,Immunoassay ,Vaccines ,medicine.diagnostic_test ,biology ,business.industry ,Gardasil ,Immunogenicity ,Papillomavirus Infections ,Confidence interval ,Vaccination ,Titer ,biology.protein ,Female ,Serostatus ,business ,medicine.drug ,Follow-Up Studies - Abstract
This quadrivalent human papillomavirus (qHPV) (HPV6, -11, -16, and -18) vaccine long-term follow-up (LTFU) study is an ongoing extension of a pivotal clinical study (FUTURE II) taking place in the Nordic region. The LTFU study was designed to evaluate the effectiveness, immunogenicity, and safety of the qHPV vaccine (Gardasil) for at least 10 years following completion of the base study. The current report presents immunogenicity data from testing samples of the year 5 LTFU visit (approximately 9 years after vaccination). FUTURE II vaccination arm subjects, who consented to being followed in the LTFU, donated serum at regular intervals and in 2012. Anti-HPV6, -11, -16, and -18 antibodies were detected by the competitive Luminex immunoassay (cLIA), and in addition, serum samples from 2012 were analyzed by the total IgG Luminex immunoassay (LIA) ( n = 1,598). cLIA geometric mean titers (GMTs) remained between 70% and 93% of their month 48 value depending on HPV type. For all HPV types, the lower bound of the 95% confidence interval (CI) for the year 9 GMTs remained above the serostatus cutoff value. The proportion of subjects who remained seropositive based on the IgG LIA was higher than the proportion based on cLIA, especially for anti-HPV18. As expected, the anti-HPV serum IgG and cLIA responses were strongly correlated for all HPV types. Anti-HPV GMTs and the proportion of vaccinated individuals who are seropositive remain high for up to 9 years of follow-up after vaccination.
- Published
- 2015
33. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015
- Author
-
Fabio Lievano, Michelle Vichnin, Suzanne M. Garland, Paolo Bonanni, Heather L. Sings, Rosybel Drury, Christine Velicer, Stan L. Block, Gonzalo Perez, Richard M. Haupt, Susanne K. Kjaer, Nicola P. Klein, Barbara J. Kuter, and Alfred J. Saah
- Subjects
Male ,Gardasil ,human papillomavirus ,safety ,surveillance ,vaccine ,Adolescent ,Adult ,Child ,Drug-Related Side Effects and Adverse Reactions ,Female ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,Humans ,Middle Aged ,Papillomavirus Infections ,Pregnancy ,Young Adult ,Product Surveillance, Postmarketing ,Pediatrics, Perinatology and Child Health ,Infectious Diseases ,Microbiology (medical) ,Medicine (all) ,Uterine cervix cancer ,Review ,Human papillomavirus vaccine ,Genital warts ,Genital system ,Autoimmune disease ,Pathology ,Clinical protocol ,Drug safety ,Middle aged ,Priority journal ,Public health ,Surveillance ,Hpv types ,Incidence ,Vaccination ,Postmarketing surveillance ,Vagina cancer ,virus diseases ,Anus cancer ,Human immunodeficiency virus infected patient ,Verruca vulgaris ,Postmarketing ,Product Surveillance ,Precancer ,Clinical trial (topic) ,Safety ,medicine.drug ,Human ,Venous thromboembolism ,medicine.medical_specialty ,Human papillomavirus ,Skin infection ,Systemic lupus erythematosus ,Cerebrovascular accident ,medicine ,Faintness ,Anaphylaxis ,Guillain Barre syndrome ,business.industry ,Pharmacoepidemiology ,Pregnant woman ,medicine.disease ,Dermatology ,Vulva cancer ,Drug surveillance program ,Licensing ,business ,Wart virus vaccine ,Vaccine - Abstract
Background: A quadrivalent human papillomavirus (HPV4) type 6/11/16/18 vaccine (GARDASIL/SILGARD®) has been licensed in many countries around the world for the prevention of cervical, vulvar, vaginal, and anal cancers and precancers, as well as external genital warts causally related to HPV types 6/11/16/18. Across 7 phase 3 clinical trials involving more than 29,000 males and females ages 9-45 years, vaccination was generally well tolerated. Because of its expected public health benefit in reducing cervical cancer and other HPV-related diseases, the vaccine has been implemented in the national vaccination programs of several countries, with over 178 million doses distributed worldwide. Methods: Extensive efforts to assess the safety of the vaccine in routine practice have been conducted over the past 9 years since licensure, including more than 15 studies in more than 1 million preadolescents, adolescents and adults from various countries. Most have been performed in the general population although there have been some in special populations (pregnant women, HIV-infected individuals and those with systemic lupus erythematosus). Results: We present a summary of the published, postlicensure safety data from active and passive surveillance. Only syncope, and possibly skin infections were associated with vaccination in the postlicensure setting. Serious adverse events, such as adverse pregnancy outcomes, autoimmune diseases (including Guillain-Barre Syndrome and multiple sclerosis), anaphylaxis, venous thromboembolism and stroke, were extensively studied, and no increase in the incidence of these events was found compared with background rates. Conclusions: These results, along with the safety data from the prelicensure clinical trials, confirm that the HPV4 vaccine has a favorable safety profile. Key policy, medical and regulatory organizations around the world have independently reviewed these data and continue to recommend routine HPV vaccination. Copyright © 2015 Wolters Kluwer Health, Inc.
- Published
- 2015
34. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study
- Author
-
Carole A. Sable, C. Joy Lipka, Alfred J. Saah, Nicholas A. Kartsonis, and Arlene Taylor
- Subjects
Adult ,Male ,Microbiology (medical) ,medicine.medical_specialty ,Antifungal Agents ,Adolescent ,Echinocandin ,Salvage therapy ,Opportunistic Infections ,Aspergillosis ,Peptides, Cyclic ,Echinocandins ,Lipopeptides ,chemistry.chemical_compound ,Pharmacotherapy ,Refractory ,Caspofungin ,Amphotericin B ,Internal medicine ,medicine ,Humans ,Child ,skin and connective tissue diseases ,Adverse effect ,Aged ,Aged, 80 and over ,Salvage Therapy ,Acquired Immunodeficiency Syndrome ,business.industry ,Organ Transplantation ,Middle Aged ,bacterial infections and mycoses ,medicine.disease ,Surgery ,Infectious Diseases ,chemistry ,Drug Therapy, Combination ,Female ,Itraconazole ,business ,medicine.drug - Abstract
Objectives . The objective was to prospectively assess the efficacy and safety of caspofungin as salvage therapy for invasive aspergillosis in patients enrolled in the caspofungin compassionate-use study. Methods . Forty-eight patients with invasive Aspergillus infections (36 with pulmonary infection, 12 with extrapulmonary or disseminated infection) were enrolled in this study. All patients were refractory to or intolerant of intravenous amphotericin B or a lipid amphotericin formulation(s). Efficacy was assessed at end of intravenous caspofungin therapy based on the clinical (symptom/sign and radiographic) response. Results . Underlying diseases included hematological malignancy (69%), organ transplant (8%), and AIDS (6%). Forty-three (90%) patients were refractory to prior antifungal treatment, including 25 patients refractory to multiple agents. Sixteen (33%) were neutropenic at study entry. Following caspofungin therapy, a favorable response was noted in 44% (20/45) of the patients, including nine (20%) and 11 (24%) patients with complete and partial responses, respectively. Caspofungin was generally well tolerated one serious drug-related adverse event was reported. Conclusions . In this study, caspofungin was an effective alternative for patients with refractory Aspergillus infections.
- Published
- 2005
35. Effects of Ritonavir on Indinavir Pharmacokinetics in Cerebrospinal Fluid and Plasma
- Author
-
Julie A. Stone, Janet Nicotera, David W. Haas, Stephen Raffanti, Alfred J. Saah, Victoria L. Harris, Benjamin W. Johnson, Jennifer Schranz, Vicki L. Bailey, Farideh B. Bowles, and Tyler S. Finn
- Subjects
Adult ,Male ,Anti-HIV Agents ,viruses ,HIV Infections ,Indinavir ,Pharmacology ,Blood–brain barrier ,Antiviral Agents ,Cerebrospinal fluid ,Pharmacokinetics ,immune system diseases ,Oral administration ,Blood plasma ,medicine ,Humans ,heterocyclic compounds ,Pharmacology (medical) ,Ritonavir ,business.industry ,Stavudine ,virus diseases ,HIV Protease Inhibitors ,Middle Aged ,biochemical phenomena, metabolism, and nutrition ,Infectious Diseases ,medicine.anatomical_structure ,Blood-Brain Barrier ,Lamivudine ,Immunoglobulin G ,Drug Therapy, Combination ,Female ,business ,medicine.drug - Abstract
Therapeutic control of human immunodeficiency virus type 1 (HIV-1) in peripheral compartments does not assure control in the central nervous system. Inadequate drug penetration may provide a sanctuary from which resistant virus can emerge or allow development of psychomotor abnormalities. To characterize the effect of ritonavir on indinavir disposition into cerebrospinal fluid, seven HIV-infected adults underwent intensive sampling at steady-state while receiving twice-daily indinavir (800 mg) and ritonavir (100 mg). Serial cerebrospinal fluid and plasma samples were obtained at 10 time points from each subject. Free indinavir accounted for 98.6% of drug in cerebrospinal fluid and 55.9% in plasma. Mean cerebrospinal fluid C max , C min , and area under the concentration-time curve from 0 to 12 h (AUC 0-12 ) values for free indinavir were 735 nM, 280 nM, and 6,502 nM h −1 , respectively, and the free levels exceeded 100 nM in every sample. The cerebrospinal fluid/plasma AUC 0-12 ratio for free indinavir was 17.5% ± 6.4%. This ratio was remarkably similar to results obtained in a previous study in which subjects received indinavir without ritonavir, indicating that ritonavir did not have a substantial direct effect on the barrier to indinavir penetration into cerebrospinal fluid. Low-dose ritonavir increases cerebrospinal fluid indinavir concentrations substantially more than 800 mg of indinavir given thrice daily without concomitant ritonavir, despite a lower total daily indinavir dose.
- Published
- 2003
36. Long-term study of a quadrivalent human papillomavirus vaccine
- Author
-
Keith S. Reisinger, Daron G. Ferris, Timothy A. Sausser, Ole Erik Iversen, Jesper Mehlsen, Heather L. Sings, Qiong Shou, Stan L. Block, Alfred J. Saah, Eduardo Lazcano-Ponce, Rudiwilai Samakoses, Archana Chatterjee, and Jaime Alberto Restrepo
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Time Factors ,Adolescent ,Disease ,Placebo ,Serology ,Genital warts ,Double-Blind Method ,Medicine ,Humans ,Papillomavirus Vaccines ,Adverse effect ,Child ,Human papillomavirus 16 ,Human papillomavirus 18 ,business.industry ,Human papillomavirus 11 ,Immunogenicity ,Papillomavirus Infections ,Vaccination ,Antibody titer ,medicine.disease ,Human papillomavirus 6 ,Regimen ,Treatment Outcome ,Pediatrics, Perinatology and Child Health ,Immunology ,Female ,business ,Follow-Up Studies - Abstract
BACKGROUND: We present a long-term safety, immunogenicity, and effectiveness study of a quadrivalent human papillomavirus (HPV4) vaccine. METHODS: Sexually naive boys and girls aged 9 to 15 years (N = 1781) were assigned (2:1) to receive HPV4 vaccine or saline placebo at day 1 and months 2 and 6. At month 30, the placebo group (n = 482) received HPV4 vaccine following the same regimen and both cohorts were followed through month 96. Subjects ≥16 years were eligible for effectiveness evaluations. The primary objective was to evaluate the long-term anti-HPV6/11/16/18 serological levels. The secondary objective was to estimate vaccine effectiveness against HPV6/11/16/18-related persistent infection or disease. RESULTS: For each of the HPV4 vaccine types, vaccination-induced anti-HPV response persisted through month 96. Among 429 subjects who received HPV4 vaccine at a mean age of 12, none developed HPV6/11/16/18-related disease or persistent infection of ≥12 months’ duration. Acquisition of new sexual partners (among those ≥16 years) was ∼1 per year. Subjects receiving HPV4 vaccine at month 30 (mean age 15 years) had a similar baseline rate of seropositivity to ≥1 of the 4 HPV types to those vaccinated at day 1 (mean age 12 years; 1.9% [9 of 474] vs 1.7% [20 of 1157]); however, 4 of the 9 subjects vaccinated at the later age were seropositive to 3 vaccine types, indicating previous HPV exposure. No new significant serious adverse events were observed for 8 years postvaccination in both genders. CONCLUSIONS: When administered to adolescents, the HPV4 vaccine demonstrated durability in clinically effective protection and sustained antibody titers over 8 years.
- Published
- 2014
37. Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Women
- Author
-
Susan Cu-Uvin, Judith A. Aberg, Beatriz Grinsztejn, Joel M. Palefsky, Triin Umbleja, Erna M. Kojic, Alfred J. Saah, Minhee Kang, Cynthia Firnhaber, Catherine Godfrey, Reena T. Allen, Jennifer Webster-Cyriaque, and Michelle S. Cespedes
- Subjects
HIV Infections ,immunogenicity ,Antibodies, Viral ,Medical and Health Sciences ,Human Papillomavirus Recombinant Vaccine Quadrivalent ,South Africa ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,vaccine safety ,Viral ,Papillomaviridae ,Cancer ,anogenital disease ,education.field_of_study ,biology ,integumentary system ,Vaccination ,virus diseases ,Viral Load ,Middle Aged ,Biological Sciences ,Infectious Diseases ,HIV/AIDS ,Female ,Infection ,Viral load ,Brazil ,Adult ,Microbiology (medical) ,Adolescent ,Drug-Related Side Effects and Adverse Reactions ,Clinical Trials and Supportive Activities ,Population ,Human Papilloma Virus Vaccine ,Microbiology ,Antibodies ,Vaccine Related ,Young Adult ,Acquired immunodeficiency syndrome (AIDS) ,Clinical Research ,medicine ,Humans ,Papillomavirus Vaccines ,Seroconversion ,education ,HPV vaccine ,business.industry ,HIV-infected women ,Prevention ,Papillomavirus Infections ,medicine.disease ,biology.organism_classification ,Virology ,United States ,CD4 Lymphocyte Count ,Good Health and Well Being ,HIV-1 ,Types 6 ,Sexually Transmitted Infections ,Immunization ,HPV and/or Cervical Cancer Vaccines ,Serostatus ,business - Abstract
BackgroundWomen infected with human immunodeficiency virus (HIV) are disproportionately affected by human papillomavirus (HPV)-related anogenital disease, particularly with increased immunosuppression. AIDS Clinical Trials Group protocol A5240 was a trial of 319 HIV-infected women in the United States, Brazil, and South Africa to determine immunogenicity and safety of the quadrivalent HPV vaccine in 3 strata based on screening CD4 count: >350 (stratum A), 201-350 (stratum B), and ≤200 cells/µL (stratum C).MethodsSafety and serostatus of HPV types 6, 11, 16, and 18 were examined. HPV serological testing was performed using competitive Luminex immunoassay (HPV-4 cLIA). HPV type-specific seroconversion analysis was done for participants who were seronegative for the given type at baseline.ResultsMedian age of patients was 36 years; 11% were white, 56% black, and 31% Hispanic. Median CD4 count was 310 cells/µL, and 40% had undetectable HIV-1 load. No safety issues were identified. Seroconversion proportions among women at week 28 for HPV types 6, 11,16, and 18 were 96%, 98%, 99%, and 91%, respectively, for stratum A; 100%, 98%, 98%, and 85%, respectively, for stratum B, and 84%, 92%, 93%, and 75%, respectively, for stratum C.ConclusionsThe quadrivalent HPV vaccine targeted at types 6, 11, 16, and 18 was safe and immunogenic in HIV-infected women aged 13-45 years. Women with HIV RNA load >10 000 copies/mL and/or CD4 count
- Published
- 2014
- Full Text
- View/download PDF
38. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18
- Author
-
Peter Sehr, Ivonne Rubio, David Radley, Michael Pawlita, Martin Müller, Hanna Seitz, Christine C. Roberts, Darron R. Brown, Alfred J. Saah, and Joseph M. Antonello
- Subjects
Male ,Time Factors ,medicine.drug_class ,viruses ,HPV vaccines ,Biology ,Monoclonal antibody ,Antibodies, Viral ,Immunoglobulin G ,Neutralization ,Pseudovirion ,Neutralization Tests ,medicine ,Humans ,Neutralizing antibody ,Randomized Controlled Trials as Topic ,Immunoassay ,Human papillomavirus 16 ,General Veterinary ,General Immunology and Microbiology ,medicine.diagnostic_test ,Human papillomavirus 18 ,Public Health, Environmental and Occupational Health ,Virology ,Antibodies, Neutralizing ,Infectious Diseases ,Clinical Trials, Phase III as Topic ,Immunology ,biology.protein ,Linear Models ,Molecular Medicine ,Female ,Antibody - Abstract
There are two approved vaccines against anogenital human papillomaviruses (HPV) and a nine-valent vaccine is currently under development. Although there are several assays available to measure antibodies elicited by HPV vaccines, there is currently no global standard for HPV antibody assays. In the current study, antibody responses to HPV16 and HPV18 among young men and women vaccinated with a quadrivalent HPV6/11/16/18 (qHPV) vaccine were assessed using three assays: a competitive Luminex immunoassay (cLIA-4) which measures antibodies directed against a single neutralizing epitope, an immunoglobulin G Luminex immunoassay (IgG-9) which measures both neutralizing and non-neutralizing antibodies, and a pseudovirion-based neutralization assay (PBNA) which functionally measures the full spectra of neutralizing antibodies. To assess HPV16 and HPV18 responses, 648 and 623 serum samples, respectively, were selected from three prior clinical trials of the qHPV vaccine. For each HPV type, the functional relationship between pairs of assay methods was estimated using a linear statistical relationship model and Pearson correlation coefficients. For both HPV16 and HPV18, the agreement between the PBNA and IgG-9 (correlation coefficients of 0.95 and 0.93, respectively) was comparable to the agreement between the cLIA-4 and IgG-9 (correlation coefficients of 0.92 and 0.92, respectively). Of 478 and 399 post-dose 3 samples that tested positive in the cLIA-4, 100% and 98% also tested positive in the IgG-9 and PBNA. The proportion of cLIA-4 seronegative post-dose 3 samples that tested positive in both the IgG-9 and PBNA was 68% (19/28) for HPV16 and 58% (71/122) for HPV18. The data demonstrate the three assays are highly correlated and reflect the measurement of neutralizing antibody. This further verifies that the IgG-9 assay, which is used to assess the immune response to an investigational nine-valent vaccine, is similarly sensitive to the PBNA for the detection of HPV16 and HPV18 neutralizing antibodies.
- Published
- 2013
39. [Untitled]
- Author
-
Neil M.H. Graham, Cynthia M. Lyles, Joseph B. Margolick, David Vlahov, Homayoon Farzadegan, Alfred J. Saah, and Jacquie Astemborski
- Subjects
medicine.medical_specialty ,biology ,Epidemiology ,business.industry ,medicine.disease ,biology.organism_classification ,Peripheral blood mononuclear cell ,Acquired immunodeficiency syndrome (AIDS) ,Immunopathology ,Internal medicine ,Immunology ,Medicine ,Viral disease ,business ,Sida ,Viral load ,Survival analysis - Abstract
Cell-associated infectious HIV-1 viral load was measured using semi-quantitative microculture techniques to determine its predictive capability for progression to AIDS or survival among HIV-1 infected injecting drug users (IDU) and homosexual men (HM). The authors followed 296 IDU and 240 HM from February 1992 through September 1995 for: (i) death, (ii) AIDS, and (iii) AIDS or bacterial infection. At baseline, viral load was quantified using microculture techniques to determine infectious units per million peripheral blood mononuclear cells (IUPM). Data were analyzed using standard statistical methods for survival analysis. Of the 536 total participants, 106 died (20%), and 98 of the 481 AIDS-free participants developed AIDS (20%). The relative hazard of AIDS for a viral load of ≥100 IUPM, relative to a negative culture (0 IUPM), was 6.73 (95% CI: 2.23–20.3) after adjusting for risk group, initial CD4+ count, and other covariates. The adjusted relative hazard of death for a viral load of 100 IUPM vs. 0 IUPM was 2.57 (95% CI: 0.97–6.80). Viral load predicted time to death within the
- Published
- 1999
40. THE EFFECT OF PROPHYLAXIS WITH DAPSONE ON DEVELOPMENT OF MYCOBACTERIUM AVIUM-INTRACELLULARE DISEASE
- Author
-
Neil M.H. Graham, Daniel S. Stein, Sharon A. Riddler, Alfred J. Saah, Clara Chu, Donald R. Hoover, Roger Detels, and John P. Phair
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,Infectious Diseases ,business.industry ,Internal medicine ,Immunology ,medicine ,Multicenter AIDS Cohort Study ,Mycobacterium avium-intracellulare ,Disease ,Dapsone ,business ,medicine.drug - Published
- 1998
41. Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection
- Author
-
Shigui Weng, Cheryl Enger, Richard A. Kaslow, Ray Apple, Dean L. Mann, John P. Phair, John W. Mellors, Alfred J. Saah, Donald R. Hoover, Roger Detels, Pamela Johnson, Stephen J. O'Brien, Mary Carrington, and Charles R. Rinaldo
- Subjects
Cellular immunity ,biology ,Proportional hazards model ,Immunology ,Multicenter AIDS Cohort Study ,Human leukocyte antigen ,biology.organism_classification ,Infectious Diseases ,Lentivirus ,Immunology and Allergy ,Viral disease ,Seroconversion ,Viral load - Abstract
BACKGROUND Host genetic factors, such as HLA alleles, play an important role in mediating the course of HIV-1 disease progression through largely undefined mechanisms. OBJECTIVES To examine the association of HLA markers with HIV-1 RNA plasma viral load and other factors associated with course of disease progression in HIV-1 infection. DESIGN AND METHODS A group of 139 HIV-1 seroconverters from the Multicenter AIDS Cohort Study had been typed for a variety of HLA markers. HIV-1 RNA plasma viral load was measured from frozen plasma specimens obtained approximately 9 months following seroconversion. CD4+ cell counts were available from the same study visit. Statistical analysis was performed using survival techniques and linear regression models to quantify the relative associations of an HLA score profile, HIV-1 RNA plasma viral load, CD4+ cell count and age with each other and with rate of progression to AIDS and death. RESULTS Cox proportional hazards models showed statistically significant differences in time to AIDS by HLA score profile category per unit increase [relative hazard (RH), 0.64; P < 0.0001], HIV-1 RNA plasma viral load per 10-fold increase (RH, 2.04; P = 0.0003), and CD4+ cell count per 100 cell (x 10(6)/l) increase (RH, 0.90; P = 0.02). Multivariate linear regression showed that viral load was 39% lower (P = 0.0001) for each unit increase in HLA score profile and 13% lower (P = 0.002) for each 100 cell (x 10(6)/l) increase in CD4+ cell count. CONCLUSION The means by which the HLA score profile influences the time to AIDS is probably through immunologic responses that affect the rate of HIV-1 replication, as manifested by the HIV-1 RNA plasma viral load during the first 6-12 months following acute infection.
- Published
- 1998
42. Human Papillomavirus, Anal Squamous Intraepithelial Lesions, and Human Immunodeficiency Virus in a Cohort of Gay Men
- Author
-
Mark E. Sherman, Heidi B. Friedman, Keerti V. Shah, Anne E. Busseniers, Richard A. Kaslow, Anthony M. Ghaffari, Richard W. Daniel, Alfred J. Saah, and William C. Blackwelder
- Subjects
Adult ,Male ,Sexually transmitted disease ,medicine.medical_specialty ,Population ,Rectum ,HIV Infections ,Gastroenterology ,Virus ,Cohort Studies ,Internal medicine ,Prevalence ,medicine ,Humans ,Immunology and Allergy ,DNA Probes, HPV ,Homosexuality, Male ,education ,Papillomaviridae ,education.field_of_study ,biology ,business.industry ,Papillomavirus Infections ,virus diseases ,Viral Load ,Condyloma Acuminatum ,Anus Neoplasms ,medicine.disease ,biology.organism_classification ,female genital diseases and pregnancy complications ,CD4 Lymphocyte Count ,Tumor Virus Infections ,Squamous intraepithelial lesion ,Cross-Sectional Studies ,Infectious Diseases ,medicine.anatomical_structure ,Lentivirus ,Immunology ,Viral disease ,business ,Carcinoma in Situ - Abstract
Cross-sectional associations between human papillomavirus (HPV), anal squamous intraepithelial lesions (SIL), and human immunodeficiency virus (HIV) were studied in a cohort of gay men. HPV DNA was detected by generic and type-specific polymerase chain reaction (PCR) probes and hybrid capture assay (HC). HPV virus load was estimated by HC relative light unit (RLU) ratio. HPV prevalence, number of HPV types detected, and HC RLU ratios were each greater in HIV-positive than HIV-negative participants. Further, among HIV-positive men, HC RLU ratio was inversely associated with CD4 cell count. SIL was more frequent in HIV-positive participants, particularly those with a CD4 cell counto200/mL and was positively associated with HPV. Men with a high HC RLU ratio were nearly 3 times more likely to have SIL than were those both PCR- and HC-negative. These data support that HIV augments HPV-associated anal disease in this population. Human papillomaviruses (HPV), particularly HPV-16 and that in the general population [10]. While that study could not assess the risk associated with HIV independently from -18, are causally associated with invasive cervical cancer and its precursors [1 ‐ 4]. Since the squamocolumnar junction be- that associated with homosexuality, cross-sectional studies have demonstrated both an increased prevalence of anal HPV tween the rectum and anus are histologically similar to the transformation zone of the uterine cervix, attention has been infection and of SIL among HIV-seropositive men, particularly those who are symptomatic or have decreased CD4 cell
- Published
- 1998
43. Predicting Clinical Progression or Death in Subjects with Early‐Stage Human Immunodeficiency Virus (HIV) Infection: A Comparative Analysis of Quantification of HIV RNA, Soluble Tumor Necrosis Factor Type II Receptors, Neopterin, and $\beta _{2}$ -Microglobulin
- Author
-
Neil M. H. Graham, Alfred J. Saah, Robert H. Lyles, Joseph B. Margolick, Roger Detels, Charles R. Rinaldo, Daniel S. Stein, Charles J. Tassoni, John P. Phair, and John A. Bilello
- Subjects
biology ,Beta-2 microglobulin ,HIV ,RNA ,Neopterin ,HIV Infections ,medicine.disease ,biology.organism_classification ,Receptors, Tumor Necrosis Factor ,Virus ,CD4 Lymphocyte Count ,chemistry.chemical_compound ,Infectious Diseases ,Immune system ,Acquired immunodeficiency syndrome (AIDS) ,chemistry ,Immunopathology ,Lentivirus ,Immunology ,medicine ,Humans ,RNA, Viral ,Immunology and Allergy ,beta 2-Microglobulin - Abstract
Quantification of human immunodeficiency virus (HIV) RNA by branched-chain DNA signal amplification, measurement of soluble tumor necrosis factor type II receptors (sTNFR-II), neopterin, beta2-microglobulin, or CD4 cell counts can be used to predict the risk of clinical progression or death in HIV infection but have not been compared in the same study. Ninety subjects were categorized into progression groups by their rate of CD4 cell decline and matched into triplets by initial CD4 cell count, age, race, and calendar time. By matched logistic regression, only the sTNFR-II and HIV RNA values were predictive of outcome across the progression groups. Categorization of baseline HIV RNA and sTNFR-II resulted in differences in progression to several clinical outcomes. sTNFR-II concentrations were the only immune marker examined that increased the prognostic utility of HIV RNA determination in early-stage subjects. Further studies in later stages of disease or after therapy are indicated.
- Published
- 1997
44. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical Features of Cytomegalovirus Retinitis at Diagnosis
- Author
-
Michael C. Smith, David V. Weinberg, Lee M. Jampol, Dorothy N. Friedberg, Kathleen Squires, L. Rickman, Allan H. Friedman, J. Hoffman, Janet L. Davis, Judith Feinberg, B. Martin, K. Tolson, Robert L. Murphy, K. Naughton, L. Eldred, Deborah Greenspan, C. Gerzack, J. O'Donell, R. Vandenbroucke, David J. Hardy, Victor Fainstein, R. Brookmeyer, M. A. Simanello, T. Flynn, John Bartlett, W. R. Freeman, C. R. Levine, M. Donithan, M. Stecens, T. J. Peterson, R. M. Webb, Steven A. Teich, Mark A. Jacobson, Linda G. Apuzzo, S. Chafey, T. Samo, M. D. Davis, J. I. Quiceno, H. Kachadoorian, P. Clogston, Y. I. Min, Henry S. Sacks, Jan A. Markowitz, J. Leslie, E. Chuang, J. M. Kline, J. Dodge, Stephen A. Spector, M. Agres-Segal, R. M. Owens, J. Brown-Bellamy, Alfred J. Saah, N. Justin, M. L. Van Natta, M. R. Isaacson, A. Irvine, N. Fink, C. LeCount, A. C. Klemm, H. Fall, D. J. Nowakowski, K. B. Collins, James P. Dunn, R. Franklin, K. Frost, J. Armstrong, S. Seiff, L. MacArthur-Chang, G. Peyman, S. Singer, Alice L. Sternberg, Curtis L. Meinert, L. Meixnert, R. King, L. C. Coleson, D. Dietrich, J. Larson, C. Severin, D. Henderly, P. Mendez, J. Brickbauer, Gary N. Holland, B. Polsky, S. Wise-Campbell, A. Addessi, M. Espinal, Tony W. Cheung, Richard Haubrich, C. Tuttle, R. Gross, B. J. Collison, A. M.K. Gilpin, Douglas A. Jabs, B. Barron, James Tonascia, R. Cheeseman, John W. Gittinger, and R. A. Lewis
- Subjects
Ganciclovir ,Foscarnet ,Ophthalmology ,business.industry ,medicine ,Cytomegalovirus retinitis ,medicine.disease ,business ,Virology ,medicine.drug - Published
- 1997
45. Seroreactivity to hepatitis E virus in areas where the disease is not endemic
- Author
-
David L. Thomas, David Vlahov, Patrice O. Yarbough, Alfred J. Saah, Sergei A. Tsarev, Robert H. Purcell, and Kenrad E. Nelson
- Subjects
Male ,Microbiology (medical) ,viruses ,medicine.disease_cause ,Hepatitis E virus ,medicine ,Humans ,Homosexuality, Male ,Substance Abuse, Intravenous ,Subclinical infection ,Immunoassay ,Hepatitis ,biology ,business.industry ,Transmission (medicine) ,virus diseases ,Hepatitis A ,Hepatitis E ,medicine.disease ,biology.organism_classification ,Virology ,digestive system diseases ,Hepeviridae ,Immunology ,Viral disease ,business ,Research Article - Abstract
If the occurrence of hepatitis E virus antibody (anti-HEV) in regions where the disease is not endemic represents infection, rates may be greater in high-risk populations and behavioral correlates may reflect recognized transmission modes. Serum samples from 300 homosexual males, 300 injection drug users (IDUs), and 300 blood donors from Baltimore, Md., were tested for anti-HEV by enzyme immunoassay. Anti-HEV was found in an unexpectedly high percentage of homosexual men (15.9%) and IDUs (23.0%). However, anti-HEV was present in a similar proportion of blood donors (21.3%) (P > 0.05), while hepatitis A, B, and C virus antibodies were more prevalent in the high-risk groups (P < 0.001). Among homosexual men, anti-HEV was not significantly correlated with a history of hepatitis, high-risk sexual practices, or sexually transmitted infections, in contrast to hepatitis A and B antibodies. Among IDUs, anti-HEV was not significantly associated with a history of hepatitis or high-risk drug-using practices, as was found with hepatitis C antibodies. In a setting without endemic hepatitis E disease, there was no evidence that anti-HEV reflected subclinical infection. Until the basis for HEV seroreactivity in such areas is elucidated, anti-HEV results should be interpreted with caution.
- Published
- 1997
46. Association between serum vitamin A and E levels and HIV-1 disease progression
- Author
-
Neil M.H. Graham, Alice M. Tang, Richard D. Semba, and Alfred J. Saah
- Subjects
Adult ,Male ,Vitamin ,medicine.medical_specialty ,medicine.medical_treatment ,Immunology ,Population ,Gastroenterology ,Cohort Studies ,chemistry.chemical_compound ,Internal medicine ,medicine ,Humans ,Vitamin E ,Immunology and Allergy ,Tocopherol ,Risk factor ,Vitamin A ,education ,Prospective cohort study ,Aged ,Acquired Immunodeficiency Syndrome ,education.field_of_study ,business.industry ,Retinol ,Middle Aged ,Prognosis ,Infectious Diseases ,Endocrinology ,chemistry ,HIV-1 ,Multivitamin ,business ,Biomarkers - Abstract
Objective: To examine the associations between serum vitamin A and E levels and risk of progression to three key outcomes in HIV-1 infection: first AIDS diagnosis, CD4+ cell decline to < 200 cells x 10 6 /l, and mortality. Design: Non-concurrent prospective study. Methods: Serum levels of vitamins A and E were measured at the enrollment visit of 311 HIV-seroprevalent homo-/bisexual men participating in the Baltimore/ Washington DC site of the Multicenter AIDS Cohort Study. Cox proportional hazards models were used to estimate the relative hazard of progression to each outcome over the subsequent 9 years, adjusting for several independent covariates. Results: Men in the highest quartile of serum vitamin E levels (≥ 23.5 μmol/l) showed a 34% decrease in risk of progression to AIDS compared with those in the lowest quartile Irelative hazard (RH), 0.66; 95% confidence interval (CI), 0.41-1.06)1. This effect was statistically significant when comparing the highest quartile of serum vitamin E to the remainder of the cohort (RH, 0.67; 95%, CI, 0.45-0.98). Associations between serum vitamin A levels and risk of progression to AIDS were less clear, but vitamin A levels were uniformly in the normal to high range (median = 2.44 μmol/l). Similar trends were observed for each vitamin with mortality as the outcome, but neither vitamin was associated with CD4+ cell decline to < 200 cells x 10 6 /l. Men who reported current use of multivitamin or single vitamin E supplements had significantly higher serum tocopherol levels than those who were not taking supplements (P = 0.0001). Serum retinol levels were unrelated to intake of multivitamin or single vitamin A supplements. Conclusions: These data suggest that high serum levels of vitamin E may be associated with slower HIV-1 disease progression, but no relationship was observed between retinol levels and disease progression in this vitamin A-replete population.
- Published
- 1997
47. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women
- Author
-
David Radley, Ivete Maldonado, Alfred J. Saah, Manuel Plata, Mauricio González, Scott Vuocolo, Claudia Nossa, Richard M. Haupt, Joaquín Luna, and Alfonso Correa
- Subjects
Pediatrics ,Viral Diseases ,lcsh:Medicine ,Uterine Cervical Neoplasms ,Cervical Cancer ,Genital warts ,law.invention ,Randomized controlled trial ,Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ,law ,Pregnancy ,Genitourinary Cancers ,Longitudinal Studies ,Young adult ,lcsh:Science ,education.field_of_study ,Human papillomavirus 16 ,Vaccines ,Multidisciplinary ,Human papillomavirus 18 ,Human papillomavirus 11 ,Immunogenicity ,Vaccination ,Obstetrics and Gynecology ,Middle Aged ,Clinical Trial ,Immunizations ,Treatment Outcome ,Infectious Diseases ,Female Genital Diseases ,Oncology ,Condylomata Acuminata ,Medicine ,Female ,Public Health ,Safety ,Cancer Prevention ,medicine.drug ,Research Article ,Adult ,medicine.medical_specialty ,Drugs and Devices ,Human Papillomavirus Infection ,Clinical Research Design ,Urology ,Population ,Sexually Transmitted Diseases ,Colombia ,Cervical intraepithelial neoplasia ,Microbiology ,Cancer Vaccines ,Young Adult ,Double-Blind Method ,Adverse Reactions ,Virology ,medicine ,Humans ,Clinical Trials ,Papillomavirus Vaccines ,education ,Biology ,Immunity to Infections ,Gynecology ,business.industry ,Genitourinary Infections ,Gardasil ,lcsh:R ,Papillomavirus Infections ,Immunity ,Cancers and Neoplasms ,Viral Vaccines ,medicine.disease ,Human papillomavirus 6 ,Uterine Cervical Dysplasia ,Genitourinary Tract Tumors ,Women's Health ,lcsh:Q ,Clinical Immunology ,Preventive Medicine ,business ,Gynecological Tumors ,Follow-Up Studies - Abstract
Background Previous analyses from a randomized trial in women aged 24–45 have shown the quadrivalent HPV vaccine to be efficacious in the prevention of infection, cervical intraepithelial neoplasia (CIN) and external genital lesions (EGL) related to HPV 6/11/16/18 through 4 years. In this report we present long term follow-up data on the efficacy, safety and immunogenicity of the quadrivalent HPV vaccine in adult women. Methods Follow-up data are from a study being conducted in 5 sites in Colombia designed to evaluate the long-term immunogenicity, effectiveness, and safety of the qHPV vaccine in women who were vaccinated at 24 to 45 years of age (in the original vaccine group during the base study [n = 684]) or 29 to 50 years of age (in the original placebo group during the base study [n = 651]). This analysis summarizes data collected as of the year 6 post-vaccination visit relative to day 1 of the base study (median follow-up of 6.26 years) from both the original base study and the Colombian follow-up. Results There were no cases of HPV 6/11/16/18-related CIN or EGL during the extended follow-up phase in the per-protocol population. Immunogenicity persists against vaccine-related HPV types, and no evidence of HPV type replacement has been observed. No new serious adverse experiences have been reported. Conclusions Vaccination with qHPV vaccine provides generally safe and effective protection from HPV 6-, 11-, 16-, and 18-related genital warts and cervical dysplasia through 6 years following administration to 24–45 year-old women. Trial Registration Clinicaltrials.gov NCT00090220
- Published
- 2013
48. Virologic and Serologic Markers of Rapid Progression to AIDS After HIV-1 Seroconversion
- Author
-
Maurice R.G. O'Gorman, Joseph B. Margolick, Denis R. Henrard, Cynthia A. Kleeberger, Ellen Taylor, Lewis K. Schrager, Roger Detels, Homayoon Farzadegan, Alfred J. Saah, Charles R. Rinaldo, John P. Phair, and Alison J. Kirby
- Subjects
Adult ,Male ,Immunology ,HIV Core Protein p24 ,Alpha interferon ,HIV Antibodies ,Neopterin ,Serology ,Cohort Studies ,chemistry.chemical_compound ,Acquired immunodeficiency syndrome (AIDS) ,Virology ,HIV Seropositivity ,medicine ,Humans ,Immunology and Allergy ,Homosexuality, Male ,Seroconversion ,Sida ,Acquired Immunodeficiency Syndrome ,biology ,Interferon-alpha ,virus diseases ,biology.organism_classification ,medicine.disease ,Biopterin ,Immunoglobulin Isotypes ,chemistry ,Disease Progression ,HIV-1 ,RNA, Viral ,Viral disease ,beta 2-Microglobulin ,Viral load ,Biomarkers - Abstract
The association between early virologic and immunologic events after human immunodeficiency virus type 1 (HIV-1) infection and progression of HIV-1 infection to acquired immunodeficiency syndrome (AIDS) was studied among 59 homosexual men with documented time of seroconversion. Epidemiologic factors, such as number of lifetime sexual partners, history of sexually transmitted diseases, and other factors, also were studied. All 17 seroconverters in the cohort who developed AIDS within 3 years (rapid progressors = RPs) were compared with 42 men without AIDS for at least 6 years seroconversion (nonrapid progressors = non-RPs). Plasma levels of HIV-1 RNA, p24 antigen, antibodies to HIV-1 structural genes, beta-2 microglobulin, neopterin, and interferon-alpha were measured at four time points: (a) the last seronegative visit, (b) the first seropositive visit, (c) the visit closest to AIDS (or the corresponding visit for the non-RPs) and (d) 6 years after seroconversion (for non-RPs). Up to seroconversion, the RPs had a significantly higher number of lifetime sexual partners than non-RPs (503 versus 171, respectively). At the first seropositive visit, RPs had significantly higher concentrations of plasma HIV-1 RNA (p < 0.01) and prevalence of p24 antigenemia (p < 0.001) and significantly lower levels of antibodies to the HIV-1 gag proteins p17 and p24 (p < 0.01-0.001) compared with non-RPs. These differences increased during follow-up visits. Antibodies to p66 and gp120 were significantly different only at the visit closet to AIDS (p < 0.001), as were beta-2 microglobulin and interferon alpha. These findings suggest that early virologic-immunologic events after HIV-1 infection may determine the rate of progression to AIDS. Anti-gag immune response may prevent rapid progression of HIV-1 disease and should be considered for future vaccine studies.
- Published
- 1996
49. USING MULTIPLE DECREMENT MODELS TO ESTIMATE RISK AND MORBIDITY FROM SPECIFIC AIDS ILLNESSES
- Author
-
John P. Phair, Roger Day, Donald R. Hoover, Yun Peng, Alfred J. Saah, and Roger Detels
- Subjects
Statistics and Probability ,Estimation ,Pediatrics ,medicine.medical_specialty ,biology ,Epidemiology ,business.industry ,Incidence (epidemiology) ,medicine.disease ,biology.organism_classification ,Pneumocystis pneumonia ,Acquired immunodeficiency syndrome (AIDS) ,Immunology ,medicine ,Dementia ,Viral disease ,Risk factor ,Sida ,business - Abstract
A simple non-parametric approach is developed to simultaneously estimate net incidence and morbidity time from specific AIDS illnesses in populations at high risk for death from these illnesses and other causes. The disease-death process has four-stages that can be recast as two sandwiching three-state multiple decrement processes. Non-parametric estimation of net incidence and morbidity time with error bounds are achieved from these sandwiching models through modification of methods from Aalen and Greenwood, and bootstrapping. An application to immunosuppressed HIV-1 infected homosexual men reveals that cytomegalovirus disease, Kaposi's sarcoma and Pneumocystis pneumonia are likely to occur and cause significant morbidity time.
- Published
- 1996
50. Vitamin A deficiency and T-cell subpopulations in children with meningococcal disease
- Author
-
Marc Bulterys, Ann Chao, Alfred J. Saah, Vincent Munyeshuli, Abel Dushimimana, Théophile Gatsinzi, and Richard D. Semba
- Subjects
CD4-Positive T-Lymphocytes ,Male ,Vitamin ,Adolescent ,Population ,CD4-CD8 Ratio ,Physiology ,Meningitis, Meningococcal ,Meningococcal disease ,chemistry.chemical_compound ,Risk Factors ,Humans ,Medicine ,Child ,education ,Developing Countries ,Subclinical infection ,education.field_of_study ,Vitamin A Deficiency ,business.industry ,Incidence ,Mortality rate ,Rwanda ,Retinol ,Infant ,medicine.disease ,Vitamin A deficiency ,Infectious Diseases ,chemistry ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Immunology ,Female ,business ,Meningitis - Abstract
Although group A meningococcal disease is a major cause of child morbidity and mortality in sub-Saharan Africa, little is known about vitamin A status and T-cell subpopulations in affected children. A prospective study of vitamin A levels and T-cell subpopulations was conducted in 41 children hospitalized for meningococcal meningitis in Butare, Rwanda, during an epidemic from September through November, 1992. The mean age of cases was 3.6 +/- 2.7 years (range 0.5-16 years). The case-fatality rate was 20 per cent; 73 per cent of the children had serum vitamin A levels consistent with subclinical deficiency (< 0.7 mumol/l), and 27 per cent had levels consistent with severe deficiency (< 0.35 mumol/l). Mean CD4 per cent was higher and CD8 per cent was lower among children with meningitis compared with known reference populations. These results suggest that meningococcal disease is characterized by T-cell subpopulation alterations and vitamin A deficiency.
- Published
- 1996
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.